RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43

Highlights
- optoTDP43 is a light-inducible model of TDP-43 proteinopathy and is neurotoxic
- RNA binding antagonizes aberrant liquid-liquid phase separation (LLPS) of TDP-43
- Acute recruitment to RNA-containing stress granules maintains TDP-43 solubility
- TDP-43 targeting oligonucleotides prevent aberrant LLPS and rescues neurotoxicity

Authors
Jacob R. Mann, Amanda M. Gleixner, Jocelyn C. Mauna, ..., Amantha Thathiah, James Shorter, Christopher J. Donnelly

Correspondence
chrisdonnelly@pitt.edu

In Brief
Mann et al. describe an optogenetic technique to generate neurotoxic TDP-43 assemblies found in ALS/FTD patient neurons. They show that aberrant phase transitions of TDP-43 are driven by its RNA binding status and develop an approach to prevent this neurotoxic process.

Mann et al., 2019, Neuron 102, 321–338
April 17, 2019 © 2019 Elsevier Inc.
https://doi.org/10.1016/j.neuron.2019.01.048
RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43

Jacob R. Mann,1,2 Amanda M. Gleixner,1,2 Jocelyn C. Mauna,1,2 Edward Gomes,4 Michael R. DeChellis-Marks,1,2,3 Patrick G. Needham,5 Katie E. Copley,1,2 Bryan Hurtle,1,2 Bede Portz,4 Noah J. Pyles,1,2 Lin Guo,4 Christopher B. Calder,1,2 Zachary P. Wills,1,2 Uday B. Pandey,3,6 Julia K. Kofler,2,7 Jeffrey L. Brodsky,5,8 Amantha Thathiah,1,3 James Shorter,4 and Christopher J. Donnelly1,2,3,8,9,*

1Department of Neurobiology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
2LiveLikeLou Center for ALS Research, University of Pittsburgh Brain Institute, Pittsburgh, PA 15213, USA
3Center for Neuroscience, University of Pittsburgh, Pittsburgh, PA 15213, USA
4Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA
5Department of Biological Sciences, Kenneth P. Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, PA 15213, USA
6Department of Pediatrics, Children’s Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA 15213, USA
7Department of Pathology, University of Pittsburgh, Pittsburgh, PA 15213, USA
8Center for Protein Conformational Diseases, Kenneth P. Dietrich School of Arts and Sciences, University of Pittsburgh, Pittsburgh, PA 15213, USA
9Lead Contact
*Correspondence: chrisdonnelly@pitt.edu
https://doi.org/10.1016/j.neuron.2019.01.048

SUMMARY

TDP-43 proteinopathy is a pathological hallmark of amyotrophic lateral sclerosis and frontotemporal dementia where cytoplasmic TDP-43 inclusions are observed within degenerating regions of patient postmortem tissue. The mechanism by which TDP-43 aggregates has remained elusive due to technological limitations, which prevent the analysis of specific TDP-43 interactions in live cells. We present an optogenetic approach to reliably induce TDP-43 proteinopathy under spatiotemporal control. We show that the formation of pathologically relevant inclusions is driven by aberrant interactions between low-complexity domains of TDP-43 that are antagonized by RNA binding. Although stress granules are hypothesized to be a conduit for seeding TDP-43 proteinopathy, we demonstrate pathological inclusions outside these RNA-rich structures. Furthermore, we show that aberrant phase transitions of cytoplasmic TDP-43 are neurotoxic and that treatment with oligonucleotides composed of TDP-43 target sequences prevent inclusions and rescue neurotoxicity. Collectively, these studies provide insight into the mechanisms that underlie TDP-43 proteinopathy and present a potential avenue for therapeutic intervention.

INTRODUCTION

Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are fatal neurodegenerative disorders characterized by the progressive loss of motor neurons of the spinal cord and motor cortex or cortical neurons of the frontal and temporal lobes, respectively. No effective treatments currently exist to halt ALS or FTD progression, and the cause(s) of these disorders remain unknown. Significant overlap of clinical, genetic, and neuropathological features among patients suggests that ALS and FTD exist on a neurodegenerative disease spectrum (Ling et al., 2013), and a number of familial ALS and/or FTD causing mutations have been identified (Nguyen et al., 2018). Despite this vast genetic heterogeneity, 97% of ALS patients and up to 45% of FTD patients exhibit a common neuropathological feature called TDP-43 proteinopathy. TDP-43 proteinopathy is characterized by the cytoplasmic deposition and nuclear clearance of the transactivation response element DNA-binding protein 43 kDa (TDP-43; TARDBP) (Neumann et al., 2006).

TDP-43 is a ubiquitously expressed, tightly regulated, and predominantly nuclear DNA/RNA-binding protein that contains two RNA-recognition motifs (RRMs) and a C-terminal glycine-rich, low-complexity domain (LCD) (Scotter et al., 2015). TDP-43 preferentially binds uracil guanine (UG)-rich RNA intronic sequences or 3′ UTR stem loop structures and influences a variety of RNA processing events, including alternative splicing, RNA trafficking, and RNA stability (Ling et al., 2013). In ALS and FTD, the protein is found in cytoplasmic inclusions that are detergent insoluble, hyperphosphorylated, p62 positive, and ubiquitinated (Scotter et al., 2015). Cytoplasmic inclusions also contain truncated TDP-43 species resulting from its N-terminal cleavage (Neumann et al., 2007). This neuropathological hallmark correlates well with regions of neurodegeneration in ALS/FTD patient tissue (Balog, 2011) and is found in postmortem tissue from patients diagnosed with Alzheimer’s disease (60%; Youmans and Wolozin, 2012) and chronic traumatic encephalopathy (80%; McKee et al., 2010). Thus, TDP-43 proteinopathy might serve as a convergence point of pathogenesis despite the diverse upstream mechanisms responsible for disease etiology across several neurodegenerative disorders.
Over 50 ALS/FTD-causing missense mutations have been identified in the TARDBP gene (Harrison and Shorter, 2017). Although rare in the total patient population, these mutations occur more frequently in familial ALS (fALS) patients (5%) as compared to patients with familial FTD (Ling et al., 2013). The majority of known ALS/FTD-causing TARDBP mutations cluster within the TDP-43 LCD, although others have been identified within the RRs (Harrison and Shorter, 2017). The location and functional impact of these mutations likely reflects the importance of these regions in disease pathogenesis. LCDs are common in RNA-binding proteins (RBPs) and mediate protein and RNA interactions through a process termed liquid-liquid phase separation (LLPS). LLPS involves the condensation of molecules into liquid-like compartments and is driven by weak, transient interactions between LCD regions and other multivalent protein or nucleic acid interaction domains (Harrison and Shorter, 2017). Following specific protein:protein, protein:RNA, and/or RNA:RNA nuclease interactions, this de-mixing process allows for intracellular compartmentalization, as observed with membraneless organelles, such as nucleoli, processing bodies (P-bodies), and stress granules (SGs) (Shin and Brangwynne, 2017). Many of these biological condensates contain high local concentrations of LCD-containing proteins, which contribute to the properties of these structures through a combination of specific and non-specific heterotypic protein and nucleic acid interactions (Harrison and Shorter, 2017; Shin and Brangwynne, 2017). Interestingly, ALS-associated mutations in the TDP-43 LCD alter LLPS behavior and enhance aggregation of the protein (Conicella et al., 2016; Johnson et al., 2009; Schmidt and Rotati, 2016). Similar observations have been reported of other RBPs implicated in neurodegeneration, where disease-linked LCD mutations or aging of droplets promotes the maturation and fibrillization of initially reversible protein assemblies (Harrison and Shorter, 2017). Although the physical processes underlying droplet solidification are unknown, these findings suggest that aberrant phase transitions drive the formation of pathological inclusions of RNA-binding proteins observed in neurodegenerative disease.

The cellular pathway(s) that promote aberrant TDP-43 phase transitions remain unclear, but evidence suggests that altered SG homeostasis contributes to the seeding of pathological inclusions. SGs are membraneless organelles that assemble in the cytoplasm via LLPS during periods of cellular stress and may reversibly inhibit non-essential protein synthesis (Anderson and Kedersha, 2008; Harrison and Shorter, 2017). In addition to mRNA, ribosomal subunits, and translation initiation factors, SGs sequester a number of RBPs mutated in fALS, including TDP-43 (Boeynaems et al., 2016). The nucleation and phase separation of these various proteins and RNAs into liquid-like droplets is required for cellular compartmentalization of SGs, and alterations of intermolecular dynamics may promote an irreversible gel-like state or fibrillization of prion-like protein components of these structures. The high local concentration of aggregate-prone proteins, like TDP-43, within SGs is thought to enhance protein self-interactions that subsequently mature into pathological inclusions (Harrison and Shorter, 2017). Supporting the role of SGs in seeding TDP-43 proteinopathy, recent work has also revealed that antisense oligonucleotide-mediated depletion of SG components ameliorates neurotoxicity in a TDP-43 rodent model (Becker et al., 2017).

Modeling TDP-43 proteinopathy has proven challenging. Current cellular and animal models rely on enhanced expression of wild-type or rare mutant variants of TDP-43 to initiate pathological aggregation; however, this approach is unreliable, and many models fail to develop inclusions that recapitulate ALS/FTD phenotypes (Philips and Rotstein, 2015). Furthermore, the lack of control over intracellular TDP-43 interactions impedes the ability to test whether cytoplasmic phase separation precedes inclusion formation and whether this process, or these inclusions themselves, are neurotoxic. A mechanistic understanding of the molecular processes that drive the formation of TDP-43 inclusions may reveal avenues for therapeutic intervention and uncover the underlying pathobiology of ALS/FTD and related neurodegenerative disorders. To this end, we developed an optogenetic method to induce TDP-43 proteinopathy with blue light and examine the mechanisms that drive the formation of intracellular inclusions. We found that homo-oligomerization of the TDP-43 LCD mediates light-induced phase separation (LIPS) capable of driving the formation of pathologically relevant inclusions. We also show that RNA binding regulates these aberrant phase transitions and TDP-43 residence in SGs. Finally, we demonstrate that aberrant TDP-43 phase transitions drive neurodegeneration and that treatment of neurons with oligonucleotides comprised of TDP-43 binding sequences inhibits inclusion formation and is neuroprotective.

**RESULTS**

**Optogenetic Modulation of TDP-43 Inclusions**

We generated an optogenetic Cry2olig-TDP-43-mCherry expression construct (optoTDP43) to selectively induce TDP-43 proteinopathy under the spatiotemporal control of light stimulation. Cry2olig is a variant of the photolyase-homologous region (PHR) of the cryptochrome 2 protein from Arabidopsis thaliana that undergoes reversible homo-oligomerization (~5 min) in response to blue light (Taslimi et al., 2014; Figure 1A, top). Due to recent findings suggesting the importance of N-terminal oligomerization in promoting higher order assembly and LLPS of TDP-43 (Afroz et al., 2017; Chang et al., 2012; Mompeán et al., 2017; Wang et al., 2018), we positioned the Cry2olig domain on the N terminus of the full-length TDP-43 protein. We first tested whether Cry2olig-mediated increases in focal concentrations of optoTDP43 protein lead to intracellular TDP-43 proteinopathy upon light exposure (Figure 1A, bottom). To monitor this event, we performed automated epifluorescence imaging of live HEK293 cells expressing the mCherry-tagged optoTDP43 protein (Figure 1B, top). Cells were intermittently imaged during a persistent blue light treatment using a 96-well light-emitting diode (LED) array positioned within a stage-top incubator (see STAR Methods for details). optoTDP43-expressing cells exposed to blue light showed a progressive depletion of nuclear optoTDP43 signal and developed significantly more cytoplasmic inclusions relative to optoTDP43-expressing cells kept in the dark over a 24-h live-imaging session (Figures 1B and 1C; Video S1). TDP-43 was not mislocalized in cells expressing Cry2olig-mCh alone with or without light exposure, as assessed by...
immunofluorescence and subcellular fractionation and western blotting (Figures S1A and S1B). TDP-43 inclusions were absent from TDP-43-mCh-expressing cells with or without light exposure during the imaging period, indicating that optoTDP43 inclusion formation is selectively driven by light-induced oligomerization of TDP-43 and not TDP-43 overexpression (Figure 1C). Consistent with this observation, size-exclusion chromatography confirmed that light treatment induced the formation of higher order optoTDP43 protein oligomers (Figures S2A and S2B, top bands). Together, these data indicate that light treatment initiates intracellular oligomerization of the optoTDP43 protein independent of overexpression-induced aggregation.

**Figure 1.** optoTDP43 Is a Light-Inducible Model of TDP-43 Proteinopathy

(A) Schematic of light-inducible TDP-43 proteinopathy approach using the Cry2olig photoreceptor and TDP-43 protein.

(B) optoTDP43 fusion protein and representative images of HEK293 cells expressing optoTDP43 exposed to blue light stimulation (bottom; ~0.3 mW/cm²; 465 nm) or darkness (top). Cell nuclei are circled. Arrow indicates optoTDP43 inclusion formation with light treatment.

(C) Percentage of cells exhibiting optoTDP43 inclusions over time using automated longitudinal live-imaging. n = 494–791 cells.

(D) Representative images of FRAP analysis images of Cry2-mCh or light-induced optoTDP43 inclusions.

(E) Quantification of FRAP analysis shows lack of signal recovery for optoTDP43 inclusions. n = 18–22 cells.

(F) Detergent-solubility fractionation and western blotting for TDP-43 of optoTDP43-expressing cells with and without light stimulation. * indicates full-length exogenous optoTDP43; + indicates optoTDP43 cleavage product; ** indicates full-length endogenous TDP-43; ++ indicates endogenous TDP-43 cleavage product.

(G–J) Immunofluorescence analysis of optoTDP43 inclusions (G and H) and ALS patient spinal cord (I and J) for pathological hallmarks p62 (G and I) and C-terminal hyperphosphorylated TDP-43 (H and J).

Data shown are mean ± SEM. ****p < 0.0001. Scale bars represent 10 μm.
A Light: OFF 1s OFF

B Cry2PHR-mCh optoLCD-mCh

C Concentration-dependent

D Cycle:

E Droplet disassembly

F Droplet stability

G Droplet size
We next evaluated whether the features of optoTDP43 inclusions recapitulate the biochemical and neuropathological hallmarks of TDP-43 proteinopathy seen in patient tissue, including detergent insolubility, N-terminal cleavage, C-terminal hyperphosphorylation, p62 co-localization, and the formation of ubiquitin-enriched inclusions (Al-Sarraj et al., 2011; Scotter et al., 2015). We first performed fluorescence recovery after photobleaching (FRAP) analysis of light-induced optoTDP43 inclusions to assess the material state of light-induced optoTDP43 inclusions. Although the Cry2-mCh signal recovered immediately, the optoTDP43 inclusions exhibited minimal signal recovery following photobleaching, indicating the formation of immobile intracellular protein assemblies (Figures 1D and 1E; Video S2). In addition, detergent-solubility fractionation and immunoblotting for TDP-43 and mCherry proteins showed that light induced a dramatic shift in optoTDP43 to the insoluble fraction and promoted N-terminal cleavage (Figures 1F and S2C), mimicking the biochemical profile observed in ALS/frontotemporal lobar degeneration (FTLD) patient tissue (Figure S2D). TDP-43-mCh-expressing cells did not display a similar shift in solubility or cleavage in the presence or absence of light when examined at the same time point (Figure 1F). Endogenous TDP-43 was also detected in the insoluble fraction and exhibited enhanced N-terminal cleavage in optoTDP43-expressing cells exposed to light (Figure 1F). Size-exclusion chromatography similarly revealed a shift of endogenous TDP-43 species to heavier fractions relative to cells in the dark (Figure S2A). These combined data suggest that optoTDP43 sequesters non-optogenetic TDP-43 proteins into light-induced insoluble fraction. This phenomenon is likely due to TDP-43-specific interactions, as Cry2olig-mCh expression did not affect endogenous TDP-43 solubility or cleavage, regardless of light exposure (Figure S2E).

We next confirmed the ability of optoTDP43 to directly recruit other non-optogenetic TDP-43 species into light-induced inclusions by co-expressing an EGFP-tagged TDP-43 construct along with optoTDP43 or Cry2-mCh alone. We found that EGFP-TDP-43 co-localized with the light activated optoTDP43 inclusions, and no such co-localization was observed with Cry2-mCh (Figure S2F). Furthermore, optoTDP43 inclusions are p62 positive (Figure 1G; 82.9%), hyperphosphorylated in the C-terminal domain (Figure 1H; 85.7%), and co-localize with ubiquitin (Figure S2G), as seen in patient tissue (see, for example, Figures 1I and 1J). Together, these data indicate that light-activated optoTDP43 inclusions exhibit the biochemical and pathological hallmarks of TDP-43 proteinopathy and may seed endogenous TDP-43 aggregation.

**Aberrant LCD Phase Transitions Drive the Formation of TDP-43 Inclusions**

Recent studies indicate that LCDs mediate the homo- and hetero-aligomerization of LCD-containing proteins through LLPS (Elbaum-Garfinkle et al., 2015; Molliex et al., 2015; Nott et al., 2015), and aberrant interactions between these low-complexity regions are hypothesized to promote the maturation or fibrillization of phase-separated droplets (Harrison and Shorter, 2017). To determine whether the TDP-43 LCD mediates the formation of optoTDP43 inclusions, we employed the optoDroplet approach (Shin et al., 2017) to study intracellular TDP-43 LCD phase separation behavior using the wild-type (WT) Cry2 PHR domain (Cry2PHR). This photoreceptor has a higher saturation concentration as compared to the lower threshold, and more potent, Cry2olig photoreceptor used to produce optoTDP43 inclusions and allowed us to detect subtle changes in droplet properties. We first generated an optogenetic construct containing the Cry2PHR photoreceptor fused to the TDP-43 LCD (optoLCD) and found that optoLCD proteins readily underwent reversible light-induced phase separation (LIPS) in response to brief pulses of blue light in HEK293 cells (Figures 2A and 2B; Video S3). These findings are consistent with studies reporting that purified TDP-43 LCD protein undergoes LIPS in vitro (Conicella et al., 2016; Sun and Chakrabarty, 2017). Light-induced clustering of the Cry2PHR photoreceptor alone did not induce droplet formation, indicating that the TDP-43 LCD drives LIPS (Figures 2A and 2B). Light-activated optoLCD granules also displayed classical properties of phase-separated liquid-like protein droplets (Brangwynne et al., 2009, 2015), undergoing fusion upon granule contact (Figure S3A) and exhibiting concentration (Figures 2C and S3B) and light-dependent droplet formation (Figure S3C). These data are consistent with light-activated optoDroplet formation of the LCDs of other RNA-binding proteins, including FUS, HNRNPA1, and DDXY (Shin et al., 2017).

To determine whether aberrant LCD interactions promote the formation of intracellular inclusions, we next examined the effects of repetitive and chronic LIPS on optoLCD droplet dynamics in live cells. We tested the wild-type TDP-43 LCD and optoLCD proteins containing three ALS-causing mutations...
and Rohatgi, 2016). Using a 10-min cycling blue light stimulation protocol to induce repetitive LIPS of the LCD, we observed gradual maturation of optoLC granules over successive cycles of droplet formation (Figures 2D and 2E; Video S4). OptoLC droplets exhibited a progressive increase in the number of persistent, irreversible optoLC granules with each successive cycle, an effect that was exacerbated by ALS-linked mutations (Figures 2E and 2F). Mutant optoLC proteins displayed more rapid conversion to stable droplets upon successive LIPS, as determined by an increased number (Figure 2F) and size (Figure 2G) of persistent granules compared to WT optoLC droplets, despite similar protein levels as determined by western blot analysis (Figure S3D). We next employed a chronic blue light stimulation paradigm to investigate whether the WT optoLC droplets matured into pathologically relevant inclusions with prolonged LCD oligomerization. Interestingly, a 4-h chronic blue light stimulation resulted in hyperphosphorylated and p62-positive optoLC inclusions (Figure 2H) that were immobile as evaluated by quantitative FRAP analysis (Figure 2I). These results indicate that TDP-43 LCD undergoes intracellular phase separation upon self-oligomerization and that maturation of LCD droplets, either through repetitive or chronic phase transitions or ALS-linked mutations, drives LCD inclusion formation.

RNA Binding Inhibits TDP-43 LCD Homo-oligomerization

Although the TDP-43 LCD undergoes intracellular LIPS with acute blue light treatment (Figure 2A), the same light stimulation paradigm did not induce a phase transition of full-length optoTDP43 (Figure S3E; Video S6), even when fused to the more potent homo-oligomerizing Cry2 photoreceptor domain (Cry2olig) (Taslimi et al., 2014). Given the ability of full-length purified TDP-43 to undergo rapid LLPS (McGurk et al., 2018; Molliex et al., 2015; Wang et al., 2018), we suspected there may be components within the intracellular environment that oppose TDP-43 LLPS in our model. The presence of the prominent TDP-43 RNA-binding domains (or RNA-recognition motifs [RRMs]), along with reports of an increased aggregation propensity of C-terminal cleavage products lacking these domains (Zhang et al., 2009), led us to hypothesize that RNA binding inhibits the ability of the full-length optoTDP43 protein to homo-oligomerize via its LCD.

To test this notion, we fused the Cry2olig photoreceptor domain to the TDP-43 RRsMs and evaluated the ability of the RRM domains to oligomerize in response to light. The enhanced homo-oligomerization of the Cry2olig photoreceptor domain allowed us to ensure that any observed inhibition of LIPS was likely a result of endogenous TDP-43 properties and not due to insufficient Cry2 activation. Although the TDP-43 LCD fused to Cry2olig domain (Cry2olig-LCD) underwent LIPS in response to blue light and mimicked the droplet-like properties seen with optoLCD assemblies (Figures 3A and 3B, top row, and S4A–S4E; Video S6), light treatment did not stimulate TDP-43 RRM phase separation (Figures 3A and 3B, bottom row; Video S6). We next generated Cry2olig fusion proteins containing both the TDP-43 RRRMs and LCD (RRRs + LCD WT) to test whether the RRM domains affect TDP-43 LCD LIPS. Strikingly, the RRRMs completely inhibited LIPS of the LCD, even when the potent Cry2olig photoreceptor was employed (Figures 3C and 3D, top row; Video S6). To test whether RNA binding to the RRRMs inhibits TDP-43 LCD oligomerization, we introduced five-point phenylalanine to leucine mutations within the RRM domains (5FL), which were previously shown to significantly impair, but not abolish, TDP-43 RNA binding (RRRs + LCD 5FL; Elden et al., 2010). Remarkably, robust induction of LIPS is observed following light stimulation (Figures 3C and 3D, bottom row; Video S6). Because Cry2olig fusion proteins containing mutated RRRMs alone (RRRs 5FL) did not show any light-induced droplet formation (Figure S4F), the recovery of LIPS in the RNA-binding deficient construct is mediated by the LCD. To ensure that RNA-binding activity, and not a conformational change in the construct, inhibited LIPS, we assessed whether the TDP-43 LCD can drive phase separation of the FUS RRM (fusRRM WT + LCD). Like the TDP-43 RRRMs, the FUS RRM fusion to the TDP-43 LCD failed to undergo LIPS (Figures 3E and 3F, top row; Video S6). However, when similar phenylalanine to leucine point mutations that compromise the RNA-binding ability of the FUS RRM were introduced (Daigle et al., 2013; fusRRM 4FL + LCD), the FUS RRM + TDP-43 LCD fusion protein underwent rapid LIPS (Figures 3E and 3F, bottom row; Video S6). These data indicate that RNA binding dictates the ability of the TDP-43 LCD to homo-oligomerize and drive LIPS.

To determine whether RNA binding also plays a role in the formation of pathological inclusions of full-length TDP-43, we performed RNA fluorescence in situ hybridization (FISH) and used an RNA dye to assess whether RNA resides within the light-induced optoTDP43 inclusions. Interestingly, RNA was absent

Figure 3. RNA Binding Prevents Light-Induced Phase Separation and Aggregation of TDP-43

(A–F) HEK293 cells expressing the Cry2olig photoreceptor fused to the TDP-43 LCD (A), TDP-43 RNA-binding regions (RRRs) (A), TDP-43 LCD and functional (WT) RRRMs (C), TDP-43 LCD and RNA-binding deficient (5FL) RRRMs (C), TDP-43 LCD fused to the functional (WT) FUS RRM (E), or TDP-43 LCD fused to FUS RNA-binding deficient (4FL) RRM (E) were exposed to acute light stimulation (1–8 s; 10% laser power; 488 nm) and normalized granule number per cell quantification is shown in right hand column (B, D, and F). n = 33–59 (A and B), 24–36 (C and D), and 31–45 cells (E and F). Data shown are mean ± SEM. (G) mRNA within full-length optoTDP43 inclusions was assessed by RNA fluorescence in situ hybridization (FISH) for poly-A tails. Arrow indicates absence of mRNA signal within inclusion. (H) Representative images of HEK293 cells expressing optoTDP43 that received mock or RNA (2.5 μg HEK293 total mRNA) treatment 4 h into a 16-h chronic blue light treatment. (I) Quantification of optoTDP43-expressing cells with cytoplasmic inclusions. Data points correspond to individual fields of view. n = 662–673 cells. (J and K) RNA FISH analysis of ALS and FTLD patient tissue targeting poly-A mRNA. TDP-43 inclusions (green, bottom rows) in spinal cord (J; sALS) and hippocampal (K; FTLD) sections both show no co-localization with mRNA signal (red). Data shown are mean ± SEM. **p < 0.01. Scale bars represent 10 μm.
Figure 4. TDP-43 LLPS and Aggregation Are Inhibited by RNA Binding

(A) Purified TDP43-MBP WT or 5FL (5 μM) were incubated for 2 h (10% dextran buffer; 150 mM NaCl) in the absence or presence of 1,6 hexanediol (10% w/v). Scale bar represents 50 μm.

(B) Representative differential interference contrast (DIC) images of purified TDP43-MBP WT or 5FL following incubation with increasing concentrations of yeast total RNA. Scale bar represents 50 μm.

(C) Representative electron micrographs of TDP-43 WT and 5FL following TEV cleavage in the absence (left) or presence (right) of yeast total RNA (15 μg). Scale bar represents 4 μm.

(D) Turbidity changes (normalized optical density 395 [OD 395] readings) of TDP-43 WT (blue) and 5FL (red) following TEV cleavage in the absence (open circles) or presence (solid circles) of yeast total RNA (15 μg).

(legend continued on next page)
in light-induced optoTDP43 inclusions (Figures 3G and S5A). Supporting the notion that RNA binding dictates the ability of the LCD to drive pathological oligomerization of TDP-43, longitudinal imaging also revealed that RNA-deficient optoTDP43 SFL formed inclusions at a significantly enhanced rate and frequency than the RNA-binding competent optoTDP43 in live cells (Figure S5B).

Because our data suggest that RNA binding inhibits LCD-driven phase transitions of TDP-43, we hypothesized that addition of exogenous RNA substrates might inhibit optoTDP43 inclusion formation. To test this hypothesis, we treated optoTDP43-expressing HEK293 cells with blue light for 16 h to induce inclusions and transfected cells with total HEK293 cell RNA 4 h after illumination. Surprisingly, there was a measurable reduction (28%) of optoTDP43 inclusion formation in cells treated with purified RNA, as compared to mock-treated cells, following light stimulation (Figures 3H and 3I). To determine whether mRNA co-localizes with TDP-43 SFL inclusions in patients, we performed RNA FISH using a poly-T probe in ALS and FTLD patient tissue and examined TDP-43/mRNA co-localization. TDP-43 inclusions lacked mRNA signal in both sporadic ALS (sALS) spinal cord (Figures 3J and S5C) and FTLD hippocampus (Figures 3K and S5C; Table S1). Taken together, we propose that RNA binding to the TDP-43 RRM domains inhibits LCD/LCD interactions, thus blocking aberrant TDP-43 phase transitions and the formation of pathological inclusions.

We next utilized purified WT TDP-43 and a TDP-43 protein with identical RRM point mutations (TDP-43 SFL; henceforth referred to as RNA-binding-deficient TDP-43) to examine whether RNA binding alters TDP-43 LLPS and aggregation in vitro. In the absence of RNA, C-terminal MBP-tagged TDP-43 WT and SFL formed liquid-like droplets at physiological salt concentrations that did not form in the presence of 1.6 hexanediol, which disrupts weak contacts between LCDs that drive LLPS (Gopal et al., 2017; Patel et al., 2007; Figure 4A). However, in the presence of increasing concentrations of total RNA, WT TDP-43 LLPS was inhibited in a dose-dependent manner (Figure 4B). In contrast, the RNA-binding-deficient TDP-43 SFL species was unaffected by exogenous RNA (Figure 4B). Upon selective cleavage of the MBP tag with TEV protease, TDP-43 WT and SFL form solid-phase aggregates (Figure 4C). Although WT and RNA-binding-deficient TDP-43 displayed similar aggregation kinetics in the absence of RNA, the addition of RNA completely inhibited WT TDP-43 aggregation (Figures 4C and 4D). The aggregation kinetics of TDP-43 SFL was initially delayed in the presence of RNA, likely due to residual RNA binding (Figure 4D), but the final extent of aggregation was identical to TDP-43 in the absence of RNA upon further incubation (Figures 4C and 4D). Moreover, the addition of RNase A (2.5 μg) 90 min after TEV cleavage reversed the initial inhibition of WT TDP-43 aggregation conferred by RNA addition (Figure 4E).

If RNA binding prevents aberrant phase separation and TDP-43 inclusion formation, then RNA-binding-deficient protein expression should generate TDP-43 proteinopathy. We therefore expressed (non-optogenetic) EGFP-tagged TDP-43 constructs containing wild-type or RNA-binding-reduced RRM domains in HEK293 cells (Figure 4F). Surprisingly, mere expression of the RNA-binding-deficient TDP-43 protein (EGFP-TDP43 5FL) generated large nuclear inclusions that were hyperphosphorylated and p62 positive (Figure 4G). When the protein’s nuclear localization sequence (NLS) was mutated (EGFP-TDP43cyto 5FL), the RNA-binding-deficient protein localized to the cytoplasm and formed hyperphosphorylated and p62-positive inclusions that resembled the neuropathology observed in ALS and FTLD (Figure 4H). This finding suggests that cytoplasmic mislocalization is an upstream event preceding formation of RNA-deficient cytoplasmic inclusions. FRAP analysis revealed that RNA-deficient TDP-43 inclusions in both the nucleus and cytoplasm did not recover from photobleaching (Figures 4I and 4J). Nuclear RNA-binding-deficient TDP-43 inclusions also exhibited slightly enhanced fluorescence recovery after photobleaching compared to the cytoplasmic RNA-deficient TDP-43. This may be due to the abundance of accessible RNA species in the nucleus, whereas RNAs destined for the cytoplasm are pre-assembled into heterogeneous RNP complexes (Köhler and Hurt, 2007). Overall, these findings indicate that RNA binding dictates the propensity for TDP-43 to form pathologically relevant inclusions.

**Impaired SG Recruitment Promotes Aberrant TDP-43 Phase Transitions**

SG components are modifiers of toxicity and pathological aggregation associated with TDP-43 overexpression in yeast, fly, and mouse models (Becker et al., 2017; Elden et al., 2010; Kim et al., 2014). SGs are composed of high concentrations of LCD-containing proteins and form through LLPS (Shin and Brangwynne, 2017), and maturation of TDP-43-containing SGs may seed pathological inclusions (Harrison and Shorter, 2017). Because RNA binding dictates the ability of TDP-43 to undergo LLPS and inclusion formation, we asked whether reducing the RNA binding ability of TDP-43 would confer enhanced SG recruitment and subsequent maturation into insoluble inclusions. Because cytoplasmic mislocalization is required for TDP-43 recruitment to SGs (Bentmann et al., 2012), we first induced SG formation in cells expressing cytoplasmic TDP-43 (EGFP-TDP43cyto) with functional (WT) or RNA-binding-deficient (5FL) RRMs and examined co-localization with known SG markers. Notably, RNA-binding-deficient TDP-43 (TDP43cyto 5FL) was excluded from SGs (Figures 4I and 4J). Since RNA-deficient TDP-43 lacks the ability to form nuclear TDP-43 inclusions (Figure 4F), we next examined cytoplasmic TDP-43 inclusions in cells expressing cytoplasmic TDP-43 with functional (WT) or RNA-binding-deficient (5FL) RRMs (Figures 4I and 4J). Impaired SG recruitment has previously been shown to favor formation of LLPS (Harrison and Shorter, 2017). Consistent with this, nuclear localization of TDP-43 was not observed in cells expressing cytoplasmic TDP-43 (EGFP-TDP43cyto) with functional (WT) RRM domains (Figures 4I and 4J). In contrast, RNA-binding-deficient TDP-43 (TDP43cyto 5FL) was excluded from SGs (Figures 4I and 4J). This suggests that RNA binding is required for localization of TDP-43 to SGs.
from endogenous SGs upon heat shock or sodium-arsenite-induced cell stress, whereas RNA-binding-competent TDP-43 was recruited to SGs (TDP-43cyto WT; SG+ granules; Figures 5A–5C). However, during our analysis, we discovered a subset of cytoplasmic WT TDP-43 granules that formed under stress conditions did not co-localize with SG markers (SG– granules) (Figures 5A and 5B). Further investigation revealed that these TDP-43 granules (SG– granules) lacked mRNA (Figure 5D) and were enlarged (Figure 5E). In contrast, cytoplasmic TDP-43 recruited to SGs (SG+) co-localized with mRNA signal (Figure 5D). FRAP analysis of these two subsets of cytoplasmic TDP-43 granules in live cells similarly revealed that TDP-43 recruited to RNA-containing stress granules (SG+) remained dynamic, whereas the excluded TDP-43 species (SG–) were static (Figures 5F and 5G; Video S7). Furthermore, TDP-43 residing in SG– inclusions were hyperphosphorylated and p62 positive (Figure S6A), thus exhibiting pathological hallmarks of TDP-43 proteinopathy. This result suggests that TDP-43 recruitment to SGs requires RNA binding and that localization to acutely formed, RNA-rich SGs promotes TDP-43 solubility, whereas TDP-43 outside of these RNA-containing assemblies is insoluble.

In support of this notion, TDP-43 5FL inclusions due to RNA-binding deficiencies did not co-localize with SG proteins in the nucleus or in the cytoplasm in HEK293 cells (Figure S6B). Furthermore, although optoTDP43 proteins were recruited to SGs upon sodium arsenite treatment, optoTDP43 inclusions of all sizes were devoid of key stress granule components (Figures S6C and S6D; Boeynaems et al., 2016) after illumination. Neuropathological analysis of ALS and FTLD patient tissue similarly revealed an absence of co-localization between TDP-43 inclusions and G3BP1/ATXN2 (Figures 5H and S6E).

Bait Oligonucleotides Rescue Aberrant TDP-43 Phase Transitions and Neurotoxicity

TDP-43 proteinopathy correlates with regions of neurodegeneration in ALS/FTD patients (Mackenzie et al., 2013). To determine whether the formation of TDP-43 inclusions is toxic to human neurons, we differentiated human ReNcell VM neural progenitor cells into cortical-like neurons and obtained highly enriched neuronal cultures (Figures S7A–S7C; Donato et al., 2007). We then utilized a lentiviral expression system to selectively express optoTDP43 and a far-red fluorescent reporter (iRFP670) in human ReNcell cortical neuron cultures under the control of the human synapsin promoter (hSyn) (Figure 6A) prior to induction of optoTDP43 inclusion formation with chronic light stimulation. Longitudinal live imaging at 30-min intervals revealed no significant neuronal loss in optoTDP43-expressing neurons kept in the dark (Figures 6B and 6C; Video S8). However, optoTDP43 neurons exposed to blue light exhibited progressive blebbing and loss of iRFP670 fluorescent signal in the soma after ~28 h of light exposure (determined by chi-square analysis; Figures 6B and 6C; Video S8). At the final 90-h time point, we observed a 4.3-fold increase in cell death in optoTDP43-expressing neurons exposed to light in comparison to those maintained in darkness (Figures 6B and 6C). No significant decrease in cell survival was recorded in neurons expressing the Cry2-mCh photoreceptor alone, regardless of light treatment (Figure 6C; Video S9). Light stimulation alone also failed to induce alterations in neuron morphology (Figure S7D) or cell viability (Figure S7E), indicating no phototoxicity due to the light exposure. Subsequent analyses revealed a striking cytoplasmic shift of optoTDP43 signal in dying cells ~1 h before cell death (Figure 6D) that was followed by formation of either large optoTDP43 inclusions (inclusions) or smaller, more circular assemblies (particles; Figure 6B). No significant differences were observed in either the overall survival patterns (Figure 6E) or the time to death following detection of either of these assembly types in individual neurons (event-death; Figure 6F). Importantly, neurons harboring either optoTDP43 assemblies exhibited reduced survival as compared to those with diffuse nuclear signal throughout the imaging period (Figure 6E). Immunofluorescence analysis of neurons at the 48 h time point confirmed the presence of hyperphosphorylated and p62-positive optoTDP43 inclusions in the cytoplasm of ReNcell neurons exposed to light (Figure 6G). However, examination of the smaller and equally toxic optoTDP43 particles revealed no co-localization with these markers (Figure 6G). These observations suggest that aberrant cytoplasmic phase transitions drive neurodegeneration and exert toxic downstream effects independent of S409–S410 phosphorylation or p62-co-localization status.

To investigate whether the neurotoxicity associated with aberrant optoTDP43 phase transitions could be mitigated through enhanced RNA binding, we designed a 2′OMe-modified RNA oligonucleotide based on a well-characterized TDP-43 binding sequence (Clip_34nt) previously shown to exhibit a high affinity for TDP-43 RRMs and a Kd of 112 nM (Ayala et al., 2011; Bhardwaj et al., 2013). We next employed the Clip_34nt to assess the ability of these bait oligonucleotides (bONs) to prevent light-induced optoTDP43 phase transitions in HEK293 cells. Cells expressing optoTDP43 were treated with either Clip_34nt or a scrambled oligonucleotide of equal length and nucleic acid composition prior to an 8-h light stimulation protocol (Figure 7A). Similar to the effect produced by total HEK293 RNA, treatment with the bONs resulted in a dose-dependent reduction in cytoplasmic optoTDP43 assemblies (Figure 7B), in contrast to the non-targeting scrambled control. To test whether preventing light-induced optoTDP43 phase transitions enhanced neuronal survival, we next performed automated longitudinal imaging of optoTDP43-expressing ReNcell cortical neurons following a 4-h pre-treatment with either Clip_34nt or the control oligonucleotide (Figure 7C). Although no significant differences were observed in cumulative risk of death, we observed a significant and dose-dependent reduction in neurotoxicity during light treatment following treatment with the bONs (Figures 7D and 7E). Decreased toxicity was associated with similar dose-dependent reductions in light-induced optoTDP43 phase transitions, both inclusions and particles (Figure 7F), and nuclear-cytoplasmic redistribution of the optoTDP43 protein (Figure 7G). Consistent with results presented above, these studies suggest that the neuroprotective effect of a TDP-43-binding oligonucleotide occurs through the prevention of aberrant and neurototoxic cytoplasmic TDP-43 phase transitions.
Figure 5. RNA Binding and Stress Granule Localization Prevent TDP-43 Inclusions
(A) Cytoplasmic EGFP-TDP43 constructs were expressed with functional (WT, top) or RNA-binding-deficient (5FL, bottom) RRMs in HEK293 cells prior to heat shock or sodium arsenite treatment and immunostaining for G3BP1 (red) and eIF4G (not shown).
(B and C) Percentage of WT (B) and 5FL (C) EGFP-TDP43 granules that co-localized with G3BP1/eIF4G were calculated (SG+/C0). n = 99–316 granules.
(D) RNA FISH targeting poly-A tails was performed to assess mRNA presence in SG+/C0 TDP-43 granules following sodium arsenite treatment. Scale bar represents 10 μm.
(E) Mean granule area for SG+ and SG− TDP-43 granules following heat shock and sodium arsenite treatment was determined by immunofluorescence. n = 24–68 granules per condition.
(F and G) HEK293 cells were co-transfected with cytoplasmic EGFP-TDP43cyto and G3BP1-mCh and exposed to sodium arsenite treatment to induce stress granule formation. TDP-43 granules that co-localized (SG+) or did not co-localize (SG−) with G3BP-mCh were photobleached (F) and fluorescence recovery curves were generated (G) to assess material state of SG+/− granules. n = 17–27 cells.
(H) Immunohistochemical analysis of ALS and FTLD spinal cord tissue was performed to determine whether patient TDP-43 inclusions contain SG proteins. Arrows or insets indicate a lack of co-localization between TDP-43 inclusions (red) and the SG components G3BP1 (top) and ATXN2 (bottom; green). Scale bar represents 20 μm.
Data shown are mean ± SEM. ****p < 0.0001.
DISCUSSION

TDP-43 proteinopathy is a pathological hallmark in several neurodegenerative disorders. Modeling this pathology has proven challenging, and no standard currently exists to reliably reproduce TDP-43 inclusions in live cells. To address this problem, we developed a photokinetic system to selectively induce TDP-43 proteinopathy that recapitulates pathological features observed in ALS/FTD and other neurodegenerative diseases. This system allowed us to study the intracellular mechanisms driving pathological phase separation. We show that intracellular phase transitions of TDP-43 are mediated by the LCD, and events which promote homo-oligomerization of the TDP-43 LCD seed neuropathological inclusions. RNA binding status dictates TDP-43 LCD-mediated oligomerization and RNA treatment blunts LLPS, aggregation of purified TDP-43, and light-induced optoTDP43 inclusion formation in live cells. Given recent evidence suggesting a role for SGs in seeding TDP-43 inclusions (Fernandes et al., 2018), we hypothesized that the heightened ability of RNA-binding-deficient TDP-43 to undergo LLPS and aggregation would confer enhanced recruitment to phase-separated SGs. Surprisingly, RNA-binding-deficient TDP-43 is excluded from acutely induced SGs and instead found in inclusions devoid of SG components. In contrast, TDP-43 recruited to SGs remained dynamic within these RNA-rich, liquid-like compartments. Because RNA binding inhibits aberrant phase transitions of TDP-43, we tested whether a TDP-43-binding oligonucleotide sequence inhibits a pathogenic event. Remarkably, treatment with the oligonucleotide mitigated the cytoplasmic mislocalization and aberrant phase transitions of optoTDP43 in response to light and rescued neurotoxicity.

Therefore, we propose that RNA binding dictates the ability of optoTDP43 to form light-induced inclusions. In this model, LCD oligomerization of RNA-bound optoTDP-43 is blocked upon Cry2-mediated increases in local protein concentration and RNA-binding-deficient optoTDP43 LCDs associate, thereby promoting inclusion formation (Figure 6A). This phenomenon could arise from a conformational change associated with nucleic acid binding, as shown for other RNA-binding proteins (Williamson, 2000). Nucleic acid binding also maintains the TDP-43 dimer and promotes solubility, potentially through an allosteric prevention of LCD:LCD interactions (Afroz et al., 2017; Sun et al., 2014). It is also possible that RNA binding impedes TDP-43 homo-oligomerization through competitive inhibition. Although the LCD appears to be dispensable for RNA binding (Buratti and Baralle, 2001), it contains an RGG motif that can mediate RNA interactions (Concella et al., 2016). Consistent with this, RNA depletion results in the in vitro oligomerization and aggregation of a C-terminal TDP-43 cleavage product lacking RRM1 and a portion of RRM2 (TDP-25; Kitamura et al., 2016). Contacts within the TDP-43 RRM2s themselves may also cooperate and play a distinct role in the TDP-43 aggregation process, as both RRM1 and RRM2 can form tetrameric assemblies in vitro (Kuo et al., 2009), and the RRM2 contains various segments capable of forming amyloid-like conformations (Guenther et al., 2018). Overall, interactions between these domains and RNA may block regions that mediate aberrant TDP-43 phase transitions. Similarly, FUS LLPS is inhibited by the nuclear import receptor karyopherin-b2 due to competitive interactions within domains that drive self-association (Guo et al., 2018; Yoshizawa et al., 2018).

Our work and other observations suggest that an altered TDP-43:RNA ratio creates an aggregation-prone environment for TDP-43 and serves as an upstream event in TDP-43 proteinopathy. This may occur due to disease-causing mutations, such as C9ORF72 hexanucleotide repeat expansions that disrupt nuclear transport dynamics, resulting in elevated cytoplasmic TDP-43 protein (Zhang et al., 2015b) and retention of RNA in the nucleus (Freibaum et al., 2015). Disease-causing mutations in the TDP-43 RMs that abolish RNA binding have not yet been described. However, disease-associated mutations within the TDP-43 LCD likely promote aberrant phase transitions of RNA-deficient TDP-43 proteins. This RNA-dependent model explains the aggregation of TDP-43 observed in overexpression models, in which insoluble inclusions may result from concentration-dependent phase transitions of cytoplasmic TDP-43 due to a lack of RNA substrates, as well as the cytoplasmic localization of TDP-43 inclusions observed in patient tissue (Scotter et al., 2015). Furthermore, this phenomenon likely serves as the convergence point for a number of pathways proposed to contribute to ALS/FTD, including altered TDP-43 expression, half-life, and clearance; disrupted nucleocytoplasmic transport;
Figure 7. Bait Oligonucleotides Inhibit Aberrant Phase Transitions of TDP-43 and Rescue-Associated Neurotoxicity

(A) HEK293 cells expressing optoTDP43 were pre-treated with non-targeting scrambled or targeting Clip_34nt RNA oligonucleotides for 30 min prior to chronic blue light stimulation (8 hr; ~0.3 mW/cm², 465 nm). Arrows indicate cytoplasmic optoTDP43 assemblies.

(B) Quantification of percentage of cells showing light-induced cytoplasmic optoTDP43 assemblies following indicated oligonucleotide treatments. n = 578–943 cells.

(C) Diagram representing timeline of oligonucleotide treatments and neuronal survival screening. optoTDP43-expressing ReNcell neurons were treated with indicated oligonucleotides 4 h prior to blue light exposure and automated longitudinal imaging.

(D) Representative images of neurons treated with 1 μM scrambled or Clip_34nt oligonucleotides prior to light exposure. Insets show optoTDP43 signal. Cell nuclei are circled.

(E) Cumulative risk-of-death plots generated from Kaplan-Meier survival curves of ReNcell neurons over time following treatment with increasing doses of scrambled (blue) or targeting Clip_34nt (red) oligonucleotides. Shades of traces indicate treatment concentration (light, 500 nM; dark, 1 μM). n = 78–121 cells.

(F) Automated object detection was utilized to determine percentage of ReNcell neurons showing optoTDP43 assemblies (inclusions + particles) over time following the indicated oligonucleotide treatments. n = 37–39 cells.

(G) N/C ratios of optoTDP43 signal were calculated over time in neurons exposed to the indicated oligonucleotide treatments. n = 34–45 cells.

+ indicates comparisons between 500 nM treatment groups; * indicates comparisons between 1,000 nM treatment groups. + or *p < 0.05; ++ or **p < 0.01; +++ or ***p < 0.001; ++++ or ****p < 0.0001. Data shown are mean ± SEM. Scale bars represent 10 μm.
and abnormal RNP assembly and trafficking (Boeynaems et al., 2016; Gopal et al., 2017; Ling et al., 2013). A TDP-43:RNA imbalance is further supported by a recent study indicating that RNAs are buffers to inhibit LLPS of nuclear-RNA-binding proteins (Maharana et al., 2018).

SG-mediated seeding may underlie the formation of TDP-43 inclusions. For example, the modulation of SG components alleviates TDP-43 inclusion formation and toxicity in overexpression models (Becker et al., 2017; Elden et al., 2010; Kim et al., 2014). Although previous studies show that both the TDP-43 RRM and LCD are necessary for SG targeting (Colombrita et al., 2009), we show that TDP-43 RNA binding is required for SG localization.

This is consistent with previous reports describing the RNA-dependent recruitment of ALS/FTD-linked FUS protein to SGs (Daigle et al., 2013). Furthermore, we observed that cytoplasmic TDP-43 excluded from acute SGs forms pathological inclusions lacking mRNA, whereas TDP-43 recruited to SGs is dynamic and mobile. This is likely due to the abundance of RNA and other LCD-containing RBPs within SGs. RNA itself has been shown to alter the properties of protein-rich droplets (Zhang et al., 2015a) and reduces droplet viscosity through dynamic protein:RNA interactions within LAF-1 droplets (Elbaum-Garfinkle et al., 2015). These dynamic protein:protein, protein:RNA, and RNA:RNA interactions within SGs likely contribute to the
liquid-like properties of these structures and may convey a diminished propensity to initiate pathological maturation or fibrilization as compared to a more homogeneous, protein-rich granule. Therefore, our findings may delineate between normal, physiological LLPS interactions, specifically in the formation of heterogeneously composed membraneless organelles and pathological homogeneous LLPS interactions prone to seed disease-associated protein inclusions (Figure 8B). However, this does not eliminate the possibility that altered SG dynamics contribute to the aggregation of TDP-43. For example, whereas RNA-containing SGs may initially inhibit TDP-43 proteinopathy, shifts in the SG composition to a more protein-saturated state might be capable of directly promoting TDP-43 LCD:LCD interactions. Consistent with this, prolonged stress was recently observed to elicit TDP-43-positive SGs that dissolve, leaving phosphorylated TDP-43 (McGurk et al., 2018). Thus, there may be many roads to TDP-43 aggregation, some of which involve SGs (Boeynaems and Gitler, 2018).

It is unclear whether aberrant phase transitions or inclusions themselves are inherently neurotoxic and/or capable of driving neurodegeneration. ALS-linked mutations in TDP-43 that increase aggregation propensity result in enhanced toxicity in a variety of in vitro and in vivo models (Janssens and Van Broeckhoven, 2013). In contrast, neurodegeneration has also been characterized prior to significant accumulation of detergent-insoluble TDP-43 species in other systems (Arnold et al., 2013). TDP-43 sequestration within artificial inclusions recapitulates loss-of-function phenotypes (Prpar Mihevc et al., 2016), and TDP-43 knockout is embryonic lethal whereas conditional knockdown models produce ALS-like phenotypes in vivo (Xu and Yang, 2014). This suggests that perturbations in TDP-43 function, such as RNA processing, may also drive neurotoxicity. Our data indicate that cytoplasmic mislocalization precedes light-induced TDP-43 particle or inclusion formation and neuronal death, and neuroprotective oligonucleotide treatment delays or prevents these events. Thus, it is possible that cytoplasmic sequestration in the form of aberrant TDP-43 assemblies may produce neurodegeneration through both gain- and loss-of-function mechanisms.

In sum, we describe an optogenetic-based method to induce controlled TDP-43 proteinopathy in live cells and establish that RNA regulates the formation of TDP-43 inclusions. Our studies indicate that aberrant phase transitions are toxic to human cortical-like neuronal cells, and future work will dissect the properties of toxic TDP-43 assemblies and the downstream processes that contribute to neurodegeneration. Finally, our data suggest bONs or bait nucleic acid (bNA) strategies can inhibit aberrant phase transitions of TDP-43, providing a potential therapeutic approach for future study.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**

- Cell culture
- Neuronal progenitor maintenance and differentiation
- ALS/FTLD human cases
- Lentiviral production and transduction
- Stress treatments
- Blue light treatments
- RNA and oligonucleotide treatments
- Bacterial growth and protein expression

**METHOD DETAILS**

- Cloning
- Detergent solubility assay
- Nuclear/cytoplasmic fractionation
- Size-exclusion chromatography
- SDS-PAGE/Western blotting
- Immunofluorescence
- Immunohistochemistry
- RNA Fluorescent In Situ Hybridization (RNA FISH)
- Cell viability assays
- Microscopy
- Recombinant protein purification
- In vitro phase separation and aggregation assays
- Electron Microscopy

**QUANTIFICATION AND STATISTICAL ANALYSIS**

- Image quantification and analysis
- Statistics

**SUPPLEMENTAL INFORMATION**

Supplemental Information can be found with this article online at https://doi.org/10.1016/j.neuron.2019.01.048.

**ACKNOWLEDGMENTS**

We thank Dr. Sami Barmada, MD, PhD (University of Michigan Medical Center) for assisting with cumulative risk of death analysis and Yunhong Huang (University of Pittsburgh, Thathiah Lab) for his assistance with the human ALS/FTD patient protein analysis. This work was supported by grants from NIH (R01NS105756 and R21NS098379 to C.J.D., R01GM099836 and R21NS090205 to J.S., and GM075061 and DK079307 to J.L.B.). Additional support was provided by the LiveLikeLou Fund at the Pittsburgh Foundation, the University of Pittsburgh Brain Institute, and a generous gift from Barbara McCormick to C.J.D. C.J.D. was supported by fellowships from Target ALS and the Frick Foundation for ALS Research. J.R.M. is a recipient of a graduate fellowship from the Center for Protein Conformational Diseases at the University of Pittsburgh. A.M.G. is a recipient of the Milton Safenowitz Postdoctoral Fellowship from the ALS Association. J.S. was supported by grants from the University of Pennsylvania Department of Biochemistry and Biophysics Pilot Grant Program, Life Extension Foundation, the ALS Association, Target ALS, and the Robert Packard Center for ALS Research at Johns Hopkins. J.K.K. was supported by the University of Pittsburgh Alzheimer’s Disease Research Center and grants from the NIH (P50AG005133).

**AUTHOR CONTRIBUTIONS**

microscopy (TEM), and RNA rescue experiments. P.G.N. and J.L.B. optimized and performed size exclusion chromatography experiments. C.B.C. built LED arrays and adaptors for stage top incubators and developed software integration for light stimulation during live microscopic imaging. Z.P.W. provided technical support with early use of photoreceptor stimulation and cloning. U.B.P. provided technical assistance with stress granules and RNA binding protein biology. J.K.K. provided human tissue and performed staining and analysis in ALS and FTLD patients’ samples. J.L.B. and J.S. provided technical support and guidance for protein biochemistry and experimental approach. A.T. provided technical expertise for protein assays and experimental design, performed soluble-insoluble fractionation from human tissue samples, and assisted in manuscript preparation. J.R.M. generated figures. J.R.M., A.M.G., and C.J.D. interpreted data and wrote the manuscript.

DECLARATION OF INTERESTS

C.J.D. and J.R.M. are inventors of intellectual property described in this manuscript and submitted as provisional patents by the University of Pittsburgh.

Received: June 20, 2018
Revised: November 25, 2018
Accepted: January 18, 2019
Published: February 27, 2019

REFERENCES


# STAR METHODS

## KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mouse monoclonal anti-alpha-tubulin</td>
<td>Sigma-Aldrich</td>
<td>Cat# T5168; RRID:AB_477579</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-ATXN2</td>
<td>Proteintech</td>
<td>Cat# 21776-1-AP; RRID:AB_10858483</td>
</tr>
<tr>
<td>Monoclonal mouse anti-digoxin</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 200-002-156; RRID:AB_2339005</td>
</tr>
<tr>
<td>Mouse monoclonal anti-eIF4G</td>
<td>Santa Cruz Biotechnology</td>
<td>Cat# sc-133155; RRID:AB_2095748</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-G3BP1</td>
<td>Proteintech</td>
<td>Cat# 13057-2-AP</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-Lamin B1</td>
<td>Abcam</td>
<td>Cat# ab16048; RRID:AB_443298</td>
</tr>
<tr>
<td>Mouse monoclonal anti-SQSTM1/p62</td>
<td>Abcam</td>
<td>Cat# ab56416; RRID:AB_945626</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-SQSTM1/p62</td>
<td>Abcam</td>
<td>Cat# ab91526; RRID:AB_2050336</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-phospho-eIF2alpha</td>
<td>Cell Signaling Technology</td>
<td>Cat# 9721S; RRID:AB_330951</td>
</tr>
<tr>
<td>Rat monoclonal anti-phospho-TDP-43 (Ser409/410), clone 1D3</td>
<td>Millipore Sigma</td>
<td>Cat# MABN14; RRID:AB_10620498</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-TDP-43 (C-terminal)</td>
<td>Proteintech</td>
<td>Cat# 12892-1-AP; RRID:AB_2200505</td>
</tr>
<tr>
<td>Rabbit polyclonal anti-TDP-43 (N-terminal)</td>
<td>Proteintech</td>
<td>Cat# 10782-2-AP; RRID:AB_615042</td>
</tr>
<tr>
<td>Mouse monoclonal anti-Ubiquitin</td>
<td>Santa Cruz Biotechnology</td>
<td>Cat# sc-8017; RRID:AB_2762364</td>
</tr>
<tr>
<td>Alexa Fluor 488 Donkey anti-mouse IgG (H+L)</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 715-545-150; RRID:AB_2340846</td>
</tr>
<tr>
<td>Alexa Fluor 488 Donkey anti-rabbit IgG (H+L)</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 711-545-152; RRID:AB_2313584</td>
</tr>
<tr>
<td>Alexa Fluor 594 Donkey anti-mouse IgG (H+L)</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 715-585-151; RRID:AB_2340855</td>
</tr>
<tr>
<td>Alexa Fluor 594 Donkey anti-rabbit IgG (H+L)</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 711-585-152; RRID:AB_2340621</td>
</tr>
<tr>
<td>Alexa Fluor 647 Donkey anti-mouse IgG (H+L)</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 711-605-150; RRID:AB_2340862</td>
</tr>
<tr>
<td>Alexa Fluor 647 Donkey anti-rabbit IgG (H+L)</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 711-605-152; RRID:AB_2492288</td>
</tr>
<tr>
<td>Alexa Fluor 647 Donkey anti-rat IgG (H+L)</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 712-605-153; RRID:AB_2340694</td>
</tr>
<tr>
<td>FITC Donkey anti-rat IgG (H+L)</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 705-095-147; RRID:AB_2340401</td>
</tr>
<tr>
<td>Cy3 Donkey anti-rat IgG (H+L)</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 712-165-153; RRID:AB_2340667</td>
</tr>
<tr>
<td>IRDye 680RD Conjugated Donkey anti-mouse IgG</td>
<td>LI-COR</td>
<td>Cat# 925-68072</td>
</tr>
<tr>
<td>IRDye 680RD Conjugated Donkey anti-rabbit IgG</td>
<td>LI-COR</td>
<td>Cat# 925-68073</td>
</tr>
<tr>
<td>IRDye 800CW Conjugated Donkey anti-mouse IgG</td>
<td>LI-COR</td>
<td>Cat# 925-32212</td>
</tr>
<tr>
<td>IRDye 800CW Conjugated Donkey anti-rabbit IgG</td>
<td>LI-COR</td>
<td>Cat# 926-32213</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Biological Samples</strong></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Human brain and spinal cord tissue</td>
<td>University of Pittsburgh Brain Institute Bank</td>
<td>N/A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Chemicals, Peptides, and Recombinant Proteins</strong></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Dulbecco’s Modified Eagle Media (DMEM), no phenol red</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# 31053028</td>
</tr>
<tr>
<td>HyClone Bovine Growth Serum (U.S.)</td>
<td>GE Healthcare Life Sciences</td>
<td>Cat# SH3054103</td>
</tr>
<tr>
<td>GlutaMAX Supplement</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# 35000079</td>
</tr>
<tr>
<td>Collagen I Rat Protein, Tail</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# A1048301</td>
</tr>
<tr>
<td>Lipofectamine 3000</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# L3000015</td>
</tr>
<tr>
<td>DNA-In Neuro Transfection Reagent</td>
<td>MTI-GlobalStem</td>
<td>Cat# GST-2100</td>
</tr>
<tr>
<td>Opti-MEM Reduced Serum Media</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# 51985034</td>
</tr>
<tr>
<td>Protease Inhibitor Cocktail</td>
<td>Sigma-Aldrich</td>
<td>Cat# P8340</td>
</tr>
<tr>
<td>PMSF Protease Inhibitor</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# 36978</td>
</tr>
<tr>
<td>32% Paraformaldehyde, EM Grade, Purified</td>
<td>Electron Microscopy Science</td>
<td>Cat# 30525-89-4</td>
</tr>
<tr>
<td>ProLong Diamond Antifade Mountant with DAPI</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# P36965</td>
</tr>
</tbody>
</table>

(Continued on next page)
## REAGENT or RESOURCE SOURCE IDENTIFIER

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phosphatase inhibitor cocktail II</td>
<td>Sigma-Aldrich</td>
<td>Cat# P5726</td>
</tr>
<tr>
<td>Phosphatase inhibitor cocktail III</td>
<td>Sigma-Aldrich</td>
<td>Cat# P0044</td>
</tr>
<tr>
<td>Sodium Arsenite Solution</td>
<td>Sigma-Aldrich</td>
<td>Cat# 1062771000</td>
</tr>
<tr>
<td>Tris</td>
<td>Sigma-Aldrich</td>
<td>Cat# T4661</td>
</tr>
<tr>
<td>NaCl</td>
<td>Millipore Sigma</td>
<td>Cat# SX0420-1</td>
</tr>
<tr>
<td>EDTA</td>
<td>Sigma-Aldrich</td>
<td>Cat# E9884</td>
</tr>
<tr>
<td>Triton X-100</td>
<td>Sigma-Aldrich</td>
<td>Cat# T9284</td>
</tr>
<tr>
<td>Sodium Deoxycholate</td>
<td>Sigma-Aldrich</td>
<td>Cat# D6750</td>
</tr>
<tr>
<td>Sodium Dodecyl Sulfate (SDS)</td>
<td>Fisher Scientific</td>
<td>Cat# BP166</td>
</tr>
<tr>
<td>Urea</td>
<td>Sigma-Aldrich</td>
<td>Cat# U5378</td>
</tr>
<tr>
<td>Thiourea</td>
<td>Sigma-Aldrich</td>
<td>Cat# T8656</td>
</tr>
<tr>
<td>CHAPS Detergent</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# 28300</td>
</tr>
<tr>
<td>Trans-Blot Turbo 5X Transfer Buffer</td>
<td>Bio-Rad</td>
<td>Cat# 1704272</td>
</tr>
<tr>
<td>4-20% Mini-PROTEAN TGX Precast Gels</td>
<td>Bio-Rad</td>
<td>Cat# 4561095</td>
</tr>
<tr>
<td>Odyssey Blocking Buffer (TBS)</td>
<td>LI-COR</td>
<td>Cat# 927-50000</td>
</tr>
<tr>
<td>Normal Donkey Serum</td>
<td>Jackson ImmunoResearch</td>
<td>Cat# 017-000-121</td>
</tr>
<tr>
<td>Immobilon-FL PVDF Membrane</td>
<td>Millipore Sigma</td>
<td>Cat# IPFL00010</td>
</tr>
<tr>
<td>Tween 20</td>
<td>VWR</td>
<td>Cat# 97062-332</td>
</tr>
</tbody>
</table>

### Critical Commercial Assays

<table>
<thead>
<tr>
<th>Critical Commercial Assays</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pierce BCA Protein Assay</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# 23225</td>
</tr>
<tr>
<td>RC DC Protein Assay</td>
<td>Bio-Rad</td>
<td>Cat# 5000122</td>
</tr>
<tr>
<td>NE-PER Nuclear and Cytoplasmic Extraction Reagents</td>
<td>Thermo Fisher Scientific</td>
<td>Cat# 78833</td>
</tr>
<tr>
<td>One-Wash™ Lentivirus Titration Kit, p24 ELISA</td>
<td>OriGene</td>
<td>Cat# TR30038</td>
</tr>
<tr>
<td>CellTiter-Glo Luminescent Cell Viability Assay</td>
<td>Promega</td>
<td>Cat# G7572</td>
</tr>
</tbody>
</table>

### Experimental Models: Cell Lines

<table>
<thead>
<tr>
<th>Experimental Models: Cell Lines</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEK293</td>
<td>ATCC</td>
<td>Cat# CRL-1573</td>
</tr>
<tr>
<td>ReNcell VM Human Neural Progenitor Cell Line</td>
<td>Millipore Sigma</td>
<td>Cat# SCC008</td>
</tr>
<tr>
<td>5-alpha Competent E. coli cells</td>
<td>New England Biolabs</td>
<td>Cat# C2987H</td>
</tr>
<tr>
<td>BL21 (DE3) E. coli cells</td>
<td>New England Biolabs</td>
<td>Cat# C25271</td>
</tr>
</tbody>
</table>

### Oligonucleotides

<table>
<thead>
<tr>
<th>Oligonucleotides</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primers for cloning, see Table S2 for sequences</td>
<td>IDT</td>
<td>N/A</td>
</tr>
<tr>
<td>2'-OMe-RNA bait oligonucleotides, see Table S2 for sequences</td>
<td>GenScript</td>
<td>N/A</td>
</tr>
</tbody>
</table>

### Recombinant DNA

<table>
<thead>
<tr>
<th>Recombinant DNA</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Plasmid: TDP43-mCh</td>
<td>Genecopoeia</td>
<td>Cat# Q0579</td>
</tr>
<tr>
<td>Plasmid: Cry2olig-mCh</td>
<td>Taslimi et al., 2014</td>
<td>Addgene Plasmid #60032</td>
</tr>
<tr>
<td>Plasmid: optoTDP43</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Plasmid: optoTDP43 5FL</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Plasmid: Cry2PHR-mCh</td>
<td>Kennedy et al., 2010</td>
<td>Addgene Plasmid #26866</td>
</tr>
<tr>
<td>Plasmid: optoLCD</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Plasmid: Cry2-NLS/NES-LCD</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Plasmid: Cry2-LCD</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Plasmid: optoRRMs</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Plasmid: optoRRMs + LCD</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Plasmid: optoRRMs + LCD 5FL</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Plasmid: optoFusRRMs + LCD</td>
<td>This paper</td>
<td>N/A</td>
</tr>
<tr>
<td>Plasmid: optoFusRRMs + LCD 5FL</td>
<td>This paper</td>
<td>N/A</td>
</tr>
</tbody>
</table>

(Continued on next page)
CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Christopher Donnelly (chrisdonnelly@pitt.edu).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Cell culture
HEK293 cells (female, purchased from ATCC) were maintained in DMEM (Thermo Fisher Scientific) supplemented with 10% HyClone Bovine Growth Serum (GE Healthcare Life Sciences) and 1X GlutaMAX (Thermo Fisher Scientific) at 37°C and 5% CO₂. Cells were seeded onto coverslips or plates coated with collagen (50 μg/mL, GIBCO) and allowed to incubate overnight prior to transfections (Lipofectamine 3000, Thermo Fisher Scientific) with 100 ng of DNA performed according to manufacturer’s instructions. Cells were plated on collagen-coated glass bottom plates for live-cell imaging, high throughput screening, and FRAP analysis. All manipulations of cells expressing optogenetic constructs were performed under red lamp illumination to avoid ambient light exposure.

Neuronal progenitor maintenance and differentiation
ReNcell VM (male, purchased from Millipore) were maintained and differentiated according to previously described protocols but with minor modifications (Donato et al., 2007). In brief, cells were maintained in proliferation media (DMEM/F-12, 1x GlutaMAX supplemented with 1x B27 (GIBCO), 2 ng/mL heparin (Sigma), 20 μg/mL bFGF (Millipore) and 20 μg/mL hEGF (Millipore). Differentiation was initiated by plating ReNcell VM onto low attachment plates in proliferation media in order to establish neurosphere production. Neurospheres were then mechanically dissociated and grown to full confluency. Cells were further differentiated in DMEM/F-12 supplemented with 1x GlutaMAX, 1x B27, 2 ng/mL GDNF (PeproTech) and 1 mM dibutyl-cAMP (Tocris) for one week and then maintained in DMEM/F-12 supplemented with 1x GlutaMAX, 1x B27, and 2 ng/mL GDNF. Neuronal differentiation was confirmed by immunofluorescence analysis of MAP2 and βIII-tubulin expression (see Figure S7) assessment of ability to fire action potentials (data not shown) prior to use.

ALS/FTLD human cases
All human brain and spinal cord tissue samples used in the present study were selected based upon primary clinical diagnoses of ALS/FTLD at the University of Pittsburgh Medical Center Alzheimer’s Disease Research Center or ALS-MDA clinic. Postmortem classification was performed for pathological characterization of TDP-43 inclusions by the University of Pittsburgh Neuropathology Department. The collection of postmortem brain and spinal cord tissue samples by the University of Pittsburgh Neurodegenerative Brain Bank and the specific experiments of this study were approved by the Committee for Oversight of Research and Clinical Training Involving Decedents (CORID) at the University of Pittsburgh.

Lentiviral production and transduction
Lentiviral transfer vectors encoding optoTDP43, Cry2-mCh or iRFP670 were co-transfected with packaging plasmids (OriGene) into HEK293T cells using the Turbofectin transfection reagent (OriGene) according to manufacturer’s instructions. Following an initial media change, lentiviral supernatant was collected at 24 and 48 hr post-transfection prior to filtration and overnight incubation at
4 °C with 1X Lentivirus concentration solution (OriGene). The following day, concentrated lentiviral supernatant was centrifuged at 3,500 x g for 25 min at 4 °C. The resulting pellet was recenterfuged at 3,500 x g for 5 min prior to re-suspension in ice-cold, sterile PBS. Pellets were then allowed to dissolve for 1-2 days at 4 °C. Resuspended lentiviral particles were then aliquoted and titers were determined utilizing the One-Wash Lentivirus Titer Kit, HIV-1 p24 ELISA (OriGene). Neuron transductions were performed by diluting lentiviral particles at an MOI of 5 in neuronal differentiation media. Media changes were performed after 48 hr of incubation and all experiments were initiated at 96 hr post-transduction.

**Stress treatments**

Sodium arsenite (0.5 mM, 30 min) and heat shock (43 °C, 45 min) treatment were used to induce stress granule formation where indicated.

**Blue light treatments**

Blue light stimulation was performed in 24-well or 6-well plates using custom-built LED arrays designed to fit plate dimensions and withstand common temperature/humidity requirements of cell culture incubators. Individual LED diodes were positioned above the culture surface to provide a range of ~0.1-0.3 mW/cm² of 465 nm light stimulation to the cultured cells.

**RNA and oligonucleotide treatments**

Total HEK293 RNA was extracted utilizing the miRNeasy RNA isolation kit (QIAGEN) according to manufacturer’s instructions. RNA oligonucleotides with 2′OMe modifications were synthesized by GenScript (see Table S2 for sequence details). For experiments utilizing HEK293 cells, total RNA (2.5 μg) or RNA oligonucleotides (200nM-1 μM as indicated) were transfected into cells using the Lipofectamine RNAiMAX reagent (Thermo Fisher) according to manufacturer’s instructions. For ReNcell neuron experiments, oligonucleotides were diluted into normal differentiation medium at the indicated concentrations prior to direct addition to cells.

**Bacterial growth and protein expression**

For purification of MBP-tagged TDP-43 WT and 5FL proteins, BL21 (DE3) E. coli cell cultures were grown at 37 °C to an OD600 of 0.6–0.9 as previously reported (Wang et al., 2018). Protein expression was induced by IPTG (1mM) prior to overnight incubation at 16 °C. Cells were then harvested by centrifugation.

**METHOD DETAILS**

**Cloning**

All full-length and truncated optoTDP43 plasmids were constructed by inserting PCR-generated fragments at the Smal restriction enzyme site by Gibson Assembly (HiFi DNA Assembly Master Mix, NEB) of Cry2olig-mCh and Cry2PHR-mCh base vectors (Plasmids 60032 and 26866, Addgene). TDP43-mCh was generated by inserting full-length TDP-43 CDS (synthesized by Genecopoeia) between the Nhel and Smal restriction enzyme sites of the Cry2olig-mCh backbone. All wild-type optoTDP43 vectors were constructed using the same TDP-43 insert. optoTDP43 constructs containing the TDP43cyclo, 5FL and/or M337V point mutations were generated from mutant TDP43 plasmids (Plasmids 84912, 84914, 98674, Addgene). Constructs containing the fusRRM (WT or 4FL) were generated by three-fragment Gibson Assembly, inserting the fusRRM fragment and TDP-43 LCD simultaneously into the Cry2olig-mCh backbone. All wild-type optoTDP43 vectors were constructed by inserting the wild-type or mutant TDP-43 fragments between the HindIII and KpnI restriction enzyme sites of EGFP-alpha-synuclein vector (Plasmid 40922, Addgene). G3BP1-mCh was generated through the insertion of the full-length G3BP1 CDS (synthesized by Genecopoeia) into the mCherry2-C1 backbone (Plasmid 54563, Addgene) at the Smal restriction site. See Table S2 for all primer sequences and backbone details.

**Detergent solubility assay**

Solubility of TDP-43 was assessed as previously described with minor modifications (van Eersel et al., 2011). In brief, cells were washed once with ice-cold PBS, lysed with modified RIPA buffer (25mM Tris-HCl pH 7.6 (Sigma-Aldrich), 150 mM NaCl (Millipore Sigma), 5 mM EDTA (Sigma-Aldrich), 1% Triton X-100 (Sigma-Aldrich), 1% sodium deoxycholate (Sigma-Aldrich), 0.1% SDS (Fisher Scientific), protease inhibitor cocktail (Sigma-Aldrich), 1 mM PMSF (Thermo Fisher Scientific), phosphatase inhibitor cocktails 2 and 3 (Sigma-Aldrich)) and incubated on ice for 10 min. Following brief sonication on ice, lysates or homogenates were centrifuged for 1 hr at 100,000 x g at 4 °C. Supernatants were collected as the detergent-soluble fraction. Protein concentrations were determined using the RC DC protein assay (Bio-Rad). Pellets were then re-suspended in RIPA buffer and re-sonicated and re-centrifuged. The resulting supernatant was discarded and pellets were re-suspended in urea buffer (30 mM Tris pH 8.5 (Sigma-Aldrich), 7 M urea (Sigma-Aldrich), 2 M thiourea (Sigma-Aldrich), 4% CHAPS (Thermo Fisher Scientific), protease inhibitor cocktail (Sigma-Aldrich), 1 mM PMSF (Thermo Fisher Scientific), phosphatase inhibitor cocktails 2 and 3 (Sigma-Aldrich)). Following brief sonication on ice, lysates were centrifuged for 1 hr at 100,000 x g at 22 °C. This final supernatant was then collected as the detergent-insoluble, urea-soluble fraction. Proteins from each fraction were then separated by SDS-PAGE and analyzed by western blot analysis.
Nuclear/cytoplasmic fractionation

Nuclear/cytoplasmic subcellular fractionation was performed utilizing NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Fisher Scientific) according to manufacturer’s instructions. Protein concentrations for individual fractions were determined using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) and subsequently analyzed by western blot.

Size-exclusion chromatography

A 90 mL Sephacryl S-300 column equilibrated in 25 mM Tris pH 7.8, 150 mM NaCl, 5 mM EDTA, 0.5% Triton X-100, 0.5% deoxycholate was calibrated with the size standards Blue Dextran (2000 kDa), Catalase (232 kDa), and Hemoglobin (60 kDa). Lysates from cells expressing optoTDP43 which had been subjected to blue light stimulation or darkness were loaded in a 0.5 mL volume and the column was run at a flow rate of 0.3 mL/min at 4 °C. An initial volume of 30 mL was passed through the column, which corresponded to the column void volume, then 2.5 mL fractions were collected. A sample from each fraction was mixed with SDS sample buffer and subjected to SDS-PAGE, followed by western blotting as described below.

SDS-PAGE/Western blotting

Prior to SDS-PAGE, protein concentrations were determined using the Pierce BCA Protein Assay (Thermo Fisher Scientific) or RC DC Protein Assay (Bio-Rad). Samples were separated by SDS-PAGE (4%–20% Mini-PROTEAN TGX Precast Gels, Bio-Rad) and transferred to PVDF membranes (Immobilon-FL, EMD Millipore) using the Trans-Blot Turbo Transfer System (Bio-Rad). Following water and TBS washes, membranes were blocked in Odyssey Blocking Buffer (Li-Cor) for 1 hr at room temperature. Membranes were then washed and incubated with primary antibodies in TBS-T (0.1% Tween) supplemented with 50% blocking buffer overnight at 4 °C. Primary antibody dilutions used were as follows: rabbit anti-TDP43 (Proteintech, 1:1000), mouse anti-α-tubulin (Sigma-Aldrich, 1:10000), rabbit anti-Lamin B1 (Abcam, 1:5000), rabbit anti-GAPDH (Sigma-Aldrich, 1:10000), mouse anti-mCherry (Novus Biologicals, 1:1000). Following TBS-T washes, membranes were incubated with secondary antibodies (Li-Cor, IRDye 680/800, 1:10000) for 1 hr at room temperature. Membranes were then washed with TBS-T and bands were visualized using the Odyssey CLx imaging system. All western blots shown are representative of results obtained from at least three biological replicates over three separate experiments.

Immunofluorescence

For standard immunofluorescence analysis, cells were then fixed with 4% PFA for 15 min at room temperature following one PBS wash. Following three additional PBS washes, cells were blocked with 5% normal donkey serum (NDS) in 0.3% Triton X-100 for 1 hr at room temperature. Primary antibodies were prepared in 1X PBS supplemented with 0.3% Triton X-100/5% NDS and cells were incubated in antibody solution overnight at 4 °C. Primary antibody dilutions used were as follows: mouse anti-SQSTM1/p62 (Abcam, 1:100), rabbit anti-SQSTM1/p62 (Abcam, 1:500), rat anti-phospho TDP-43 (S409/410), Clone 1D3 (EMD Millipore, 1:200), rabbit anti-G3BP1 (Proteintech, 1:500), mouse anti-α-tubulin (Sigma-Aldrich, 1:10000), mouse anti-ATXN2 (Proteintech, 1:400), rabbit anti-TAR (Santa Cruz, 1:300), mouse anti-digoxin (Jackson ImmunoResearch, 1:200), mouse anti-ubiquitin (Santa Cruz, 1:200). Following three PBS washes, secondary antibodies were diluted in 0.3% Triton X-100/5% NDS and incubated with cells for 1-2 hr at room temperature. Cells were then washed and coverslips were mounted onto slides (ProLong Diamond Antifade Mounting Media with DAPI, Invitrogen) to be visualized by confocal microscopy.

For total RNA staining, cells were fixed in 100% methanol for 15 min at −20 °C. Following three PBS washes, cells were incubated in SYTO® RNAscope Green Fluorescent Cell Stain (Thermo Fisher Scientific) staining solution (500 nM in PBS) for 20 min at room temperature. Cells were then washed three additional times in PBS prior to blocking and counterstaining as described above.

All images and quantification are representative of two or more independent experiments with at least three biological replicates per experiment. Random fields of view (9-16 per experiment) were acquired for quantification. This was performed utilizing unbiased, automated imaging protocols generated in Nikon Elements imaging software to position an automated stage. These positions were repeatedly imaged for longitudinal imaging. All images were acquired using identical settings within each experiment.

Immunohistochemistry

Formalin-fixed, paraffin-embedded human hippocampus and cervical spinal cord sections of ALS/FTLD subjects retrieved from the Neurodegenerative Brain Bank at the University of Pittsburgh, following protocols approved by the University of Pittsburgh Committee for Oversight of Research and Clinical Training Involving Decedents (CORID). Following antigen retrieval with Target Retrieval Solution, pH 9 (Dako Agilent), immunofluorescence staining was performed using the following primary antibodies: TIA1 (1:1000, Abcam), Ataxin 2 (1:50, Proteintech), G3BP1 (1:100, Proteintech) and pTDP-43 (1D3, 1:500, kindly provided by Manuela Neumann, Helmholtz Zentrum, Munich, Germany). Immunofluorescence signal was visualized using Alexa Fluor 488 and Cy3 labeled secondary antibodies (both 1:200, Jackson ImmunoResearch) and DAPI nuclear counterstain (1:1000, Thermo Scientific).

RNA Fluorescent In Situ Hybridization (RNA FISH)

RNA-FISH using PolyT (TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTT/3Dig_N) (Exiqon) or scramble control (5DigN/GTGTAACACGTCTA TAGGCCCA) (Batch 233334, Exiqon) probes was conducted as previously described but with minor modifications (Zhang et al., 2015b). In short, cells were fixed in 3.2% PFA (Electron Microscopy Science), permeabilized for 10 min in 0.3% Triton X-100.
(Sigma-Aldrich), equilibrated for 10 min in 1X SSC (Thermo Fisher Scientific) and then incubated in 40% formamide (Sigma-Aldrich) at 55°C for 10 min. Hybridization buffer (100% formamide, 1 mg/mL BSA Fraction V (Fisher Scientific), 20 mM ribonucleoside vanadyl complex (Sigma-Aldrich), 0.1M NaPO₄, 20X SSC) and then probe mixture (10 g/L salmon sperm (Thermo Fisher Scientific), 20 mg/mL E. Coli tRNA (Thermo Fisher Scientific), 80% formamide, 25 μM RNA-Probe preheated to 85°C) were added to the cells for 2 hr at 55°C. Next, the cells were washed with 40% formamide, 1X SSC, TBS-50 pH 7.4, 5M NaCl (Thermo Fisher Scientific) 1M Tris pH 7 (Thermo Fisher Scientific), 1M Tris, pH 8 (Thermo Fisher Scientific Scientific)), and then 1X PBS. Following a cross-linking step with 3.2% PFA and 0.3% Triton X-100, the cells were immunostained and washed with IF Buffer (TBS-50, 0.5 g BSA Fraction V, Protease-free BSA (Fisher Scientific)) and then incubated in blocking buffer (TBS-50, 5% Normal Donkey Serum). Finally, the cells were incubated with primary antibodies at 4°C overnight, and the following day were washed with IF buffer and incubated with secondary antibodies for 1 hr at room temperature. Additional washes with IF Buffer, TBS-50, MgCl₂, and 1X PBS were performed prior to mounting coverslips with ProLong Diamond Antifade Mounting Media and visualized by confocal microscopy.

**Cell viability assays**

Analysis of cell viability was performed utilizing the CellTiter Glo Luminescent Cell Viability Assay (Promega) according to manufacturer’s instructions. Treatment of cells with 0.1% Triton X-100 for 1 hr served as negative viability controls. Raw luminescence values were normalized to control group means and compared across experimental conditions. At least eight biological replicates were utilized per group for all experiments.

**Microscopy**

**Live-cell imaging**

All live-cell imaging experiments were performed on a Nikon A1 laser-scanning confocal microscope system outfitted with a Tokai HIT stagetop incubator utilizing 40X and/or 60X oil immersion objectives (CFI Plan Apo Lambda 60X Oil, Nikon; CFI Plan Fluo 40X Oil, Nikon). Following transfections and/or treatments, medium was changed to phenol red-free growth medium (GIBCO) and cells were allowed to equilibrate on the preheated (37°C and 5% CO₂) stagetop incubator for 10 min prior to imaging. Acute blue light stimulation was achieved by utilizing the 488nm laser line and the stimulation module within Nikon Elements imaging software. Activation duration varied from 1-8 s and laser power ranged from 1%–20% as indicated in different experiments. Stimulation regions of interest (ROIs) were drawn over fields of view prior to image acquisition. Following 2-5 baseline images, laser stimulation was performed and cells were imaged for up to 1 hr post-activation. Timing and order of image acquisition was alternated across experiments between experimental groups. Data presented are representative of at least two independent experiments utilizing three or more biological replicates per experiment.

**Fluorescence Recovery After Photo-bleaching (FRAP) Imaging**

Initially, granules or inclusions were identified using a 60X oil immersion objective by confocal microscopy and a 2x2 μm² bleaching ROIs were drawn over objects of interest. Reference ROIs of the same size were drawn in adjacent, non-bleached cells to control for photo-bleaching. Following 2-5 baseline images, objects were bleached for 500 ms using 50% laser power (488nm or 594 nm laser lines) and cells were imaged for up to 5 min post-bleaching without delay. Data presented are representative of three or more independent experiments utilizing at least two biological replicates per experiment.

**High-throughput LED Screening**

Following transfection or transduction, plates were placed into a pre-warmed Tokai HIT stage-top incubator and allowed to equilibrate for 30 min prior to imaging. Custom 96-well LED arrays were positioned above wells to provide blue light stimulation (~0.3 mW, 465 nm) and were interfaced with Nikon Elements imaging software to cooperate with imaging protocols. Communication between the LED array and microscope occurred through a 5 V analog output transmitted from a Texas Instruments BNC-2110 triggering device. Voltage signals were interpreted by a microcontroller by taking real-time voltage measurements corresponding to a specific light group combination. Through the use of a map function, the software was able to assign a value to each light group and turn the group on or off following the reading of the corresponding value by the microcontroller. Automated imaging protocols were designed and executed utilizing the Jobs module within Nikon Elements imaging software. In brief, the microscope was first programmed to perform three sequential baseline plate scans prior to light exposure. Epifluorescent images were acquired with a Prime 95B CMOS camera (Photometrics) using the ET-dsRED filter set (Chroma). Nine fields of view were imaged over time per well in duplicate per experiment per condition. Baseline images were acquired every 10 min for 30 min in total. This was followed by simultaneous blue light stimulation and image acquisition for up to 24 hr. Every 10 min during the stimulation period, LED diodes were programmed to sequentially switch off and allow for image acquisition. Following completion of imaging within wells, LED diodes were programmed to switch back on to resume light stimulation and a subsequent set of diodes was programmed to turn off to allow for imaging. This pattern was repeated throughout the remainder of the imaged wells to complete the plate scan.

**Recombinant protein purification**

TDP-43-MBPWT and TDP-43-MBP 5FL proteins were purified as previously reported (Wang et al., 2018). In brief, cells were harvested by centrifugation, resuspended in TDP-43 binding buffer (20mM Tris–Cl pH 8.0, 1 M NaCl, 10mM imidazole, 10% (v/v) glycerol, 1mM DTT), supplemented with complete EDTA-free protease inhibitor cocktail, and lysed via sonication. The protein
was purified over Ni-NTA agarose beads (QIAGEN) and eluted from the beads using 20mM Tris–Cl pH 8.0, 1 M NaCl, 300mM imidazole, 10% (v/v) glycerol, 1mM DTT. The eluate was further purified over amylose resin (NEB) and eluted using 20mM Tris–Cl pH 8.0, 1 M NaCl, 10mM maltose, 10% (v/v) glycerol, 1mM DTT. The protein was concentrated, flash frozen in liquid N₂, and stored as aliquots in –80°C until further use.

**In vitro phase separation and aggregation assays**

To induce formation of droplets, the proteins were first buffer exchanged into 20mM HEPES (pH 7.4), 150mM NaCl, and 1mM DTT using a Micro Bio-Spin P-6 Gel column (Bio-Rad). The protein was then centrifuged at 16,000 rpm for 10 min to remove any pre-formed aggregates and the protein concentration was measured via a Bradford assay. LLPS was initiated with the addition of 10% dextran (final buffer conditions of 5 μM TDP43, 15mM HEPES (pH 7.4), 150mM NaCl, and 1mM DTT with the indicated amounts of total yeast RNA) and droplets were imaged using DIC microscopy.

To measure aggregation kinetics, TDP-43 was thawed and centrifuged at 16,000 rpm for 10 min. Protein concentration was measured via Bradford and TDP-43 WT or 5FL were diluted to a final concentration of 5 μM (in 20mM HEPES (pH 7.0), 150mM NaCl, 1mM DTT, with indicated quantities of RNA). Aggregation was initiated by cleavage of the MBP tag using 5 μg/mL TEV protease and monitored via turbidity measurements using a TECAN M1000 plate reader.

**Electron Microscopy**

Transmission electron microscopy (TEM) of purified TDP-43 WT and 5FL aggregates was performed as described previously (Guo et al., 2018). In brief, following the aggregation assays described above, 10μL of each sample was adsorbed onto 300-mesh Formvar/carbon-coated copper grids (Electron Microscopy Sciences, Hatfield, PA) and stained with 2% (w/v) uranyl acetate. Excess uranyl acetate solution was removed prior to drying of the grids. Samples were then imaged using a JEOL-1010T12 transmission electron microscope.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

**Image quantification and analysis**

All image visualization and quantification was performed utilizing Nikon Elements Imaging Software and analyses were performed in a double-blind fashion. For fixed-cell image quantification of stress granule co-localization and granule size, 4-5 fields of view were analyzed per condition. EGFP-TDP43 granules were examined and percentages of granules co-localizing with stress granule markers (G3BP1, eIF4G) were calculated. Maximum intensity projections for each field of view were generated and granule area was determined using automated object detection.

For FRAP imaging experiments, mean fluorescence intensity was tracked within bleaching ROIs over time. Intensity values were corrected for photo-bleaching utilizing reference ROIs drawn within adjacent, non-bleached cells in the imaging field. Fluorescence intensity values were converted to percentages of baseline (pre-bleach) fluorescence intensity means, with minimum fluorescence intensity values collected throughout the imaging period set to 0%, and percentage fluorescence recovery to baseline values was plotted over time.

Time-lapse image sequences acquired during high-throughput LED screening were analyzed utilizing automated object recognition to identify intracellular optoTDP43 particles and inclusions. Objects were defined by fluorescence intensity and object area thresholding. The number of cells containing detected objects were tracked over time and divided by the total number of cells within the imaging field to generate percentage of cells with inclusions for each time point within the imaging sequence. Analysis of neuronal survival in longitudinal imaging datasets was performed through monitoring of the far-red iRFP670 fluorescent reporter. Cell death was defined by somatic rounding, neurite retraction/blebbing and loss of fluorescence signal. Times-of-death were recorded as the last time point at which neurons were observed to be alive and were used to generate Kaplan-Meier survival curves.

Quantification of light-induced granule formation and dissociation was performed using the spot detection function within Nikon Elements imaging software. Granules were identified according to size and contrast thresholding. Granule number per cell was monitored over time in pre-identified cells that were labeled by an ROI. Raw granule number per cell values were first normalized to baseline values per cell over time. In order to calculate normalized granule number per cell over time, a weighted baseline intensity and cell area was determined. Baseline cell fluorescence intensity and area were determined from the image acquired prior to light stimulation and from this means were calculated across all experimental groups to control for differences in protein concentration and cell size. Total group baseline mean fluorescence intensity and cell area were then used to weight granule number values per cell by dividing individual cell values by total group means. For granule dissociation rate quantification, raw granule number per cell values were first normalized to baseline values. Normalized granule number values were then converted to percentages of each individual cell’s maximum granule number per stimulation cycle. Mean percentages of cell maximum granule number were then plotted over time for each stimulation cycle.
Statistics
Statistical significance was calculated by Graphpad Prism software (Version 7.03) and resulting P values less than or equal to 0.05 were deemed to be significant. Unpaired Student’s t tests were used to determine statistical significance in datasets comparing two variables. Two-way ANOVAs with Sidak Post hoc analysis was used for comparisons of FRAP and granule formation/intracellular inclusion screening curves. Pearson’s correlations were performed to determine $r^2$ values between datasets. Exponential decay nonlinear regression analysis was performed to compare optoLCD dissociation curves across groups. For survival analysis, Kaplan-Meier estimates were used to generate survival curves and Gehan-Breslow-Wilcoxon tests were used to compare across groups. Cumulative risk-of-death curves were generated as described previously (Malik et al., 2018) using custom scripts in RStudio. Sample sizes for previously published experimental paradigms matched or exceed those established in the literature across. $n$ values described in text and figure legends represent number of cells per experimental group, unless otherwise indicated, across multiple independent experiments (see Figure Legends for details).
Supplemental Information

RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43

Jacob R. Mann, Amanda M. Gleixner, Jocelyn C. Mauna, Edward Gomes, Michael R. DeChellis-Marks, Patrick G. Needham, Katie E. Copley, Bryan Hurtle, Bede Portz, Noah J. Pyles, Lin Guo, Christopher B. Calder, Zachary P. Wills, Udai B. Pandey, Julia K. Kofler, Jeffrey L. Brodsky, Amantha Thathiah, James Shorter, and Christopher J. Donnelly
Figure S1

A

Light: OFF 16 hr

B

<table>
<thead>
<tr>
<th>Cry2-mCh</th>
<th>Light:</th>
<th>-</th>
<th>+</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>C</td>
<td>N</td>
</tr>
<tr>
<td>WB: TDP-43</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>kDa:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WB: α-tubulin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>kDa:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WB: Lamin B1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>kDa:</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure S1. Chronic blue light stimulation alone does not induce mislocalization of endogenous TDP-43, Related to Figure 1.

(A-B) HEK293 cells expressing Cry2olig-mCh were exposed to chronic blue light stimulation (16h, ~0.3 mW/cm², 465 nm) and analyzed for mislocalization of endogenous TDP-43. (A) Cells exposed to chronic blue light stimulation (bottom) or darkness (top) both show no cytoplasmic mislocalization of endogenous TDP-43 (green) by immunofluorescence. Cell nuclei are circled. (B) Cell lysates were collected following chronic blue light stimulation (lanes 3-4) or darkness (lanes 1-2) and separated into nuclear (N; lanes 1, 3) and cytoplasmic (C; lanes 2, 4) fractions. Western blot analysis of endogenous TDP-43 shows no cytoplasmic mislocalization of TDP-43 with or without blue light stimulation. Scale bar = 10 µm.
Figure S2. Chronic blue light stimulation promotes the formation of high-molecular-weight optoTDP43 oligomers and recruitment of non-optogenetic TDP-43 to inclusions, Related to Figure 1. (A-B) Cell lysates from HEK293 cells expressing optoTDP43 were collected and analyzed by size exclusion chromatography. Samples were collected from cells either exposed to stimulation with blue light (16h, ~0.3mW/cm², 465 nm, bottom) or kept in darkness (top). The void volume of the column was determined with blue dextran (2000 kDa). Column fractions were subjected to SDS-PAGE and western blot analysis for TDP-43. The molecular weight standards are indicated to the right of the representative blots. The elution peak of column size standards (232 kDa and 60 kDa) are indicated by arrows at the bottom of the gel. (B) optoTDP43 proteins exposed to blue light stimulation demonstrate a shift towards higher-molecular weight species (fractions 1-3, indicated by asterisks), indicating light-induced oligomerization. (C) Lysates from optoTDP43-expressing cells exposed to chronic blue light treatment (16h, ~0.3mW/cm², 465 nm) or darkness were collected and separated into detergent-soluble (lanes 1, 3) and RIPA-insoluble, urea-soluble (lanes 2, 4) fractions. Western blot analysis of mCherry proteins shows an enhanced shift of full-length and n-terminal cleaved optoTDP43 products in the detergent-insoluble fraction. (D) ALS/FTLD patient tissue from the hippocampus and spinal cord was separated into detergent-soluble (lanes 1, 3) and RIPA-insoluble, urea-soluble (lanes 2, 4) fractions prior to western blot analysis of TDP-43. (E) Cell lysates collected from Cry2-mCh-expressing cells following chronic blue light stimulation (lanes 2, 4) or darkness (lanes 1, 3) were separated into detergent-soluble (lanes 1, 2) and RIPA-insoluble, urea-soluble (lanes 3, 4) fractions. Western blot analysis probing for endogenous TDP-43 shows no recruitment of TDP-43 to the insoluble fraction with or without chronic blue light stimulation. (F) To confirm the ability of optoTDP43 to recruit non-optogenetic TDP-43 species into light-induced inclusions, HEK293 cells were co-transfected with either optoTDP43 (bottom) or the photoreceptor-only control Cry2olig-mCh (top) and EGFP-TDP43. optoTDP43-expressing cells exposed to chronic blue light stimulation (16h, ~0.3mW/cm², 465 nm) show co-localization of light-induced inclusions with EGFP-TDP43 (indicated by arrows). Light-induced Cry2olig-mCh clusters show no co-localization with EGFP-TDP43 signal, indicating a TDP-43:TDP-43 interaction-dependence of recruitment to induced optoTDP43 inclusions. Cell nuclei are circled. Scale bar = 10 µm. (G) Cells expressing optoTDP43 were exposed to chronic blue light stimulation (16h, ~0.3mW/cm², 465 nm, bottom) or darkness (top) and immunostained for ubiquitin (green). Light-induced optoTDP43 inclusions strongly co-localize with ubiquitin signal (indicated by arrows). Cell nuclei are circled. Scale bar = 10 µm.
Figure S3

A. Fusion Events

B. Protein expression (a.u.)

C. Light intensity-dependence

D. WB: mCherry

E. WB: α-tubulin
Figure S3. optoLCD granules display properties of phase-separated droplets and full-length optoTDP43 does not form optoDroplets, Related to Figure 2.

(A) Representative images of individual optoLCD granules showing fusion events following acute blue light stimulation (1 sec, 1% laser power, 488 nm). optoLCD granules underwent fusion and subsequent relaxation upon granule:granule contact, suggesting a liquid-like state of light-induced LCD granules. (B) Representative images of optoLCD particle formation following acute blue light stimulation (1 sec, 1% laser power, 488 nm) in cells expressing increasing concentrations of optoLCD proteins (as determined by relative fluorescence intensity). (C) Cells expressing optoLCD were exposed to acute blue light stimulation of increasing laser intensity (1 sec, 1-10% as indicated, 488 nm) and normalized granule number per cell was tracked over time. optoLCD proteins displayed enhanced phase transition responses following acute blue light stimulation of increasing light input, indicating a tunable property of light-induced LCD phase transitions as a function of activated photoreceptor molecules. n = 25-67 cells per laser setting. (D) Western blot analysis of WT and mutant optoLCD protein expression levels. (E) Full-length optoTDP43 was expressed in HEK293 cells exposed to acute blue light stimulation (1 sec, 10% laser power, 488 nm) to determine whether full-length TDP-43 could undergo LIPS. No optoTDP43 granule formation was observed in response to acute blue light stimulation. Data shown are mean +/- S.E.M. Scale bars = 10 µm.
Figure S4

A

Light: OFF 1s OFF

Cry2olig-LCD

Pre-stim 30 sec 120 sec 300 sec

B

optoLCD

Cry2olig-LCD

Cry2PHR_274 LCD/IDR_414 mCh

Cry2olig-LCD

Cry2olig_274 LCD/IDR_414 mCh

D

Concentration-dependence

Cry2olig-LCD

Number granule per cell (norm. to area/fluor. int.)

E

Light intensity-dependence

Cry2olig-LCD

Number granule per cell (norm. to area/fluor. int.)

F

Light: OFF 1s OFF

RRMs 5FL

Cry2olig RRM1WT RRM2WT -RNA Binding

Pre-stim 30 sec 120 sec 300 sec
Figure S4. Cry2olig-LCD confers an enhanced phase separation response to light, Related to Figure 3.

(A-B) HEK293 cells expressing either optoLCD (top) or the Cry2olig modified photoreceptive domain fused to the TDP-43 LCD (Cry2olig-LCD, bottom) were subjected to acute blue light stimulation (1 sec, 1% laser power, 488 nm) and granule formation was tracked over time. (B) Quantification of normalized granules per cell over time shows an enhanced phase transition response to light when the TDP-43 LCD is fused to the Cry2olig domain versus the WT Cry2PHR domain. n = 25-48 cells per construct. Data shown are mean +/- S.E.M. (C) Representative images of individual Cry2olig-LCD granules undergoing fusion events following acute blue light stimulation (1 sec, 1% laser power, 488 nm). As was observed with optoLCD droplets, Cry2olig-LCD granules underwent fusion and relaxation upon granule:granule contact. (D) A Pearson’s correlation was executed to analyze the protein concentration-dependence of Cry2olig-LCD phase transitions in response to acute blue light stimulation (1 sec, 10% laser power, 488 nm). Baseline fluorescence intensity was plotted against maximum granule number per cell during the imaging period. Data points shown are representative of individual cells. n = 26 cells. (E) Cry2olig-LCD-expressing cells were exposed to acute blue light stimulation of increasing laser intensity (1 sec, 1-10% as indicated, 488 nm) and normalized granule number per cell was quantified post-stimulation. Again, an enhanced phase separation response was observed following blue light stimulation of increasing intensity. n = 50-81 cells per laser setting. (F) Cells expressing a protein containing the TDP-43 RRMs with RNA-binding mutations fused to the Cry2olig photoreceptor (RRMs 5FL) were exposed to acute blue light stimulation (1 sec, 10% laser power, 488 nm). No droplet formation is observed following light stimulation, suggesting the TDP-43 LCD is necessary for LIPS behavior. Data shown are mean +/- S.E.M. Scale bars = 10 µm.
Figure S5

**A**

- OptoTDP43 | RNA
- Light OFF
- Light ON

**B**

- Light ON
- % Cells with aggregates
- Time (hr)
- TDP43-mCh
- optoTDP43
- optoTDP43

**C**

- ALS/FTLD
  - pTDP-43 | mRNA | DAPI
  - Hippocampus
  - Spinal cord

- FTLD-TDP43
  - pTDP-43 | mRNA | DAPI
  - Hippocampus

- sALS
  - pTDP-43 | Scrambled probe | DAPI
  - Spinal cord
Figure S5. TDP-43 inclusions in patient tissue and optoTDP43 system show an absence of RNA, Related to Figure 3.

(A) optoTDP43 was expressed in HEK293 cells that were exposed to chronic blue light stimulation (16h, ~0.3mW/cm², 465 nm) to induce optoTDP43 inclusion formation. Cells were then fixed in ice-cold methanol and stained with SYTO RNAselect non-selective RNA dye to determine whether optoTDP43 inclusions contained any RNA species, in addition to mRNA. optoTDP43 inclusions do not appear to co-stain with SYTO RNAselect dye, suggesting there are no RNA species contained within inclusions. (B) HEK293 cells expressing WT optoTDP43 (blue), RNA-binding-deficient optoTDP43 5FL (red), or non-optogenetic TDP43-mCh (black) were chronically stimulated with blue light (~0.3mW/cm², 465 nm) and simultaneously imaged over time in an automated microscopy screen to assess whether RNA-binding affects full-length TDP-43 inclusion formation. Quantification of percentage of cells with inclusions over time shows a significantly increased rate of light-induced inclusion formation with reduced RNA-binding efficiency (optoTDP43 5FL, red). n = 113-239 cells per construct. (C) Additional representative images of mRNA FISH analysis of ALS/FTLD patient tissue. Hippocampal and spinal cord sections from two FTLD cases (C9ORF72-FTLD, top left; FTLD-TDP43, top right) and one ALS case (sporadic ALS, bottom left) were examined by immunohistochemistry and RNA FISH. In all cases, no co-localization was observed between mRNA and pTDP-43 signal. Data shown are mean +/- S.E.M. ****, p < .0001. Cell nuclei are circled. Scale bars = 10 µm.
Figure S6. RNA-deficient TDP-43 inclusions do not co-localize with stress granule components, Related to Figure 5.

(A) HEK293 cells expressing EGFP-TDP43cyto were immunostained for hyperphosphorylated TDP-43 (top row, red) or p62 (bottom row, red) and G3BP1 (purple) following sodium arsenite treatment. (B) Representative images of cells containing TDP-43 5FL and TDP-43cyto 5FL inclusions immunostained for stress granule proteins G3BP1 (red) and eIF4G (purple). (C-D) HEK293 cells expressing optoTDP43 were subjected to sodium arsenite treatment (top row), chronic blue light stimulation (16 hr, ~0.3 mW/cm², 465 nm) (bottom row), or darkness (middle row) and immunostained for known stress granule components G3BP1 (green) and eIF4G (purple) (C) or ATXN2 (green) and TIAR (purple) (D). Cells treated with sodium arsenite (top row) show that optoTDP43 can be recruited to stress granules through the activation of endogenous cellular stress pathways. However, optoTDP43 inclusions (indicated by arrows) induced with blue light stimulation do not co-localize with any of the tested stress granule markers. Scale bars = 10 µm. Cell nuclei are circled. (E) Representative images of neuropathological examination of TDP-43 inclusions and SG component proteins (G3BP1, top rows; ATXN2, bottom rows) in FTLD-TDP and ALS/FTLD hippocampal sections. Arrows indicate lack of co-localization between SG components and TDP-43 inclusions. Scale bars = 50 µm.
**Figure S7**

**A**

- **Neurosphere Preparation**
- **Proliferation**
- **Neuronal Differentiation**
- **Neuronal Maintenance**

**Proliferation Media:**
- DMEM/F12 + Glut
- B27
- Heparin (2 ng/mL)
- bFGF (20 μg/mL)
- hEGF (20 μg/mL)

**Stage I Media:**
- DMEM/F12 + Glut
- B27
- GDNF (2 ng/mL)
- d,b,cAMP (1 mM)

**Stage II Media:**
- DMEM/F12 + Glut
- B27
- GDNF (2 ng/mL)

**B**

- **MAP2**
- **βIII-tubulin**
- **DAPI**

**C**

- Cell viability (normalized to control)
- **MAP2/βIII-tub+**

**D**

- Light: 48 hr
- **Dark**
- **+Light**
- **Triton**

**E**

- **48 hr**
- **n.s.**
- **Cell viability (normalized to control)**
- **Dark**
- **+Light**
- **Triton**
Figure S7. ReNcell VM cortical differentiation yields a highly neuronally-enriched culture, Related to Figure 6.

(A) ReNcell VM neuronal differentiation protocol schematic. (B) Representative immunofluorescence images of ReNcell VM neurons (differentiation day 18) following the differentiation protocol outlined in (A). MAP2 (green) and βIII-tubulin (red) are shown at 20X (top) and 60X (bottom) magnification. (C) Quantification of the percentage of MAP2/βIII-tubulin double-labeled cells shows a highly enriched neuronal population following the outlined differentiation protocol. n = 260 cells. (D-E) ReNcell neurons were exposed to chronic blue light stimulation (48 hr, ~0.3 mW/cm², 465 nm) or darkness prior to examination of neuronal morphology (D) and cell viability, as assessed by measurements of ATP levels (E) (CellTiter-Glo, Promega). No differences in morphology (D) or cell viability (E) were observed between neurons in blue light or darkness conditions. Treatment with 0.1% Triton X-100 served as a positive death control. Scale bars = 20 μm.
**Supplementary Table 1.** ALS/FTD patient information and scoring, related to Figures 3 and 4

**Supplementary Table 2.** Primer Sequences and cloning information, related to Star Methods

**Movie S1.** optoTDP43 chronic stimulation longitudinal imaging, related to Figure 1

**Movie S2.** optoTDP43 inclusion FRAP analysis, related to Figure 1

**Movie S3.** Cry2PHR vs optoLCD light induced phase separation, related to Figure 2

**Movie S4.** optoLCD vs. optoLCD$^{M377V}$, optoLCD$^{Q331K}$, and optoLCD$^{A321V}$ repetitive light induced phase separation, related to Figure 2

**Movie S5.** Lack of optoTDP43 light induced phase separation, related to Figure 3

**Movie S6.** Cry2olig LCD RRMs and FUS RRM + LCD light induced phase separation, related to Figure 4

**Movie S7.** Cytoplasmic TDP-43 FRAP within and outside of G3BP+ stress granules, related to Figure 5

**Movie S8.** optoTDP43 neuronal survival imaging, related to Figure 6

**Movie S9.** Cry2-mCh neuronal survival imaging, related to Figure 6